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ABSTRACT
IN VITRO AND IN VIVO IMMUNOMODULATORY
EFFECTS OF EXTRACELLULAR VESICLES
Mehmet S¸ahin
M.S. in Molecular Biology and Genetics
Supervisor: Assoc. Prof. I˙hsan Gu¨rsel
December, 2013
The major theme of this thesis was to characterize and understand the im-
munomodulatory potential of extracellular vesicles (EVs) isolated from different
mouse and human cell lines on immune cells. To this end, we first purified and char-
acterized the particle nature of exosomes and microparticles (MPs) and exosomes by
AFM and DLS analyses. Next, we documented their in vitro or in vivo differential
uptake/internalization kinetics by immune cells. Finally, we tested the potential ap-
plication of EVs as a drug delivery system. The physicochemical characterization
studies confirmed that EVs were in vesicular form and upon reconstitution followed
by lyophilization they retained their original sizes (i.e. size ranges were 100-150 nm
for exosomes, and 250-500 nm for MPs, respectively). MPs derived from mouse cell
lines (macrophage, T-cell and fibroblast) were stained and administered in vitro and
in vivo to track their internalization by immune cells. When incubated in culture,
origins of MPs greatly affected uptake rate and ratio by different immune cells. This
differential internalization pattern of distinct MPs was reproduced when they were
injected i.p. to mice. When incubated in culture B-cells took up the most MPs from
fibroblast origin cells. Macrophages of peritoneal exudate cells took up RAW264.7
derived MPs at the highest level upon 24h post-ip injection. We tested whether MPs
have a role in transportation or presentation of bacterial products during an ongo-
ing infection by adhering circulating pathogenic by-products and carrying them to
distant immune cells. Our data suggest that MPs could contribute to the severity of
ongoing infection in vivo, since MPs from different cells can adhere distinct ligands
such as LPS or DNA or even RNA and transmit these ligands to naive innate im-
mune cells augmenting the immunostimulatory response raised against these ligands.
Lastly, the immunotherapeutic potential of EVs harboring immunosuppressive syn-
thetic oligodeoxynucleotide sequence namely, A151 was tested following dehydration-
rehydration method on mouse splenocytes. EV-associated A151 displayed improved
inhibition of immune activation triggered by TLR7/8 and TLR9 ligands on spleen
cells. When taken together, this study established that various types of EVs derived
from different cells induces plethora of activities on immune cells. Furthermore, EVs
are potential drug carrier systems when loaded externally with suitable agents and
can be harnessed in immunotherapy of diseases.
Keywords: Exosome, microparticle, TLR, immunosuppressive DNA, immunomodu-
lation .
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O¨ZET
HU¨CRE DIS¸I KESECI˙KLERI˙N I˙N VI˙TRO VE I˙N VI˙VO
I˙MMU¨NMODU¨LATO¨R ETKI˙LERI˙
Mehmet S¸ahin
Moleku¨ler Biyoloji ve Genetik, Yu¨ksek Lisans
Tez Yo¨neticisi: Doc¸. Dr. I˙hsan Gu¨rsel
Aralık, 2013
Bu tezin ana konusu, deg˘is¸ik fare ve insan hu¨cre hatlarından elde edilen, hu¨creler arası
iletis¸imi sag˘layan partiku¨llerin bag˘ıs¸ıklık sistemi hu¨creleri u¨zerindeki olası etkilerini an-
lamak ve aras¸tırmaktır. Bu amac¸la o¨ncelikle hu¨cre dıs¸ı kesecikleri izole edip partiku¨ler
yapılarını atomik gu¨c¸ mikroskopu (AFM) ve dinamik ıs¸ık sac¸ılması (DLS) metodları kul-
lanarak analiz ettik. Ek olarak bu partiku¨llerin in vitro ve in vivo olarak bag˘ıs¸ık sistemi
hu¨creleri tarafından hu¨cre ic¸ine alınma kinetig˘ini de belgelemeye c¸alıs¸tık. Son olarak da ilac¸
tas¸ıma sistemi olarak olası kullanımlarını tanımladık. Keseciklerin fiziko-kimyasal karak-
terizasyonları DLS ve AFM ile yapılarak, bunların liyofilizasyon sonucu kesecik yapılarını
korudukları ve boyutlarının deg˘is¸medig˘i go¨sterildi (Ekzosomlar 100-150 nm boyutlarında,
mikropartiku¨ller ise 250-500 nm boyutlarında). Fare hu¨cre hatlarından elde edilen mikropar-
tiku¨ller (Makrofaj, T hu¨cresi ve Fibroblast) boyanarak in vitro ve in vivo olarak bag˘ıs¸ıklık
sistemi hu¨crelerince alımları takip edildi.Hu¨cre ku¨ltu¨ru¨ c¸alıs¸malarında mikropartiku¨llerin
kaynag˘ının deg˘is¸ik bag˘ıs¸ıklık sistemi hu¨crelerince alım oranını o¨nemli derecede etkiledig˘i
go¨zlemlendi. Intraperitonal olarak da farelere enjekte edilen mikropartiku¨llerin hu¨cre ic¸ine
alım farkları go¨sterilmis¸tir. Ku¨ltu¨rde dalak hu¨creleri ile inku¨be edildig˘inde fibroblastlar
tarafından u¨retilmis¸ vesiku¨llerin c¸og˘unlug˘u B hu¨creleri tarafından alınırken, Ip enjeksiyonun-
dan 24 saat sonra peritonal sıvı hu¨crelerinin RAW 264.7 tarafından sentezlenen mikropar-
tiku¨lleri en yu¨ksek du¨zeyde aldıg˘ı go¨zlemlenmis¸tir. Daha sonra mikropartiku¨llerin enfek-
siyon sırasında patojenlere bag˘lanarak bakteri u¨ru¨nlerinin tas¸ınmasında ve uzak yerlerdeki
bag˘ıs¸ıklık sistemi hu¨crelerine sunulmasında rol alıp almadıg˘ı sorgulandı. Farklı mikropar-
tiku¨llerin LPS, DNA ya da RNA gibi farklı ligandlara bag˘lanarak bunları uyarılmamıs¸
bag˘ıs¸ıklık sistemi hu¨clerine ilettig˘ini ve immu¨n aktivasyonu artırdıg˘ı go¨zlenlenmis¸tir. Bu
bulgular mikropartiku¨llerin in vivo enfeksiyonun du¨zeyine katkı sag˘ladıg˘ını is¸aret etmek-
tedir. Son olarak, bu keseciklerin potansiyel terapo¨tik o¨zellikleri sentetik bag˘ıs¸ık sistemi
baskılayıcı bir oligodeoksinu¨kleotid olan A151 dehidrasyon-rehidrasyon yo¨ntemi ile dalak
hu¨clerinde test edilmis¸tir. A151 ic¸eren kesecikler TLR7/8 ve TLR9 ligandları ile uyarılan
dalak hu¨creleri u¨zerinde daha etkin bir baskılama go¨stermis¸tir. Sonuc¸ olarak bu c¸alıs¸ma
deg˘is¸ik hu¨creler tarafından u¨retilen keseciklerin bag˘ıs¸ık sistemi hu¨creleri u¨zerinde bir c¸ok
etkisi oldug˘unı go¨stermis¸tir. Ek olarak keseciklerin potansiyel bir ilac¸ tas¸ıma sistemi olarak
dıs¸arıdan yu¨klenebilen uygun ajanlar oldug˘u ve hastalıkların tedavisinde kullanılabileceg˘i
anlas¸ılmıs¸tır.
Anahtar so¨zcu¨kler : Eksozom, mikrokesecik, TLR, immunbaskılayıcı DNA.
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TRIF TIR domain containing adaptor inducing IFN-γ
Chapter 1
Introduction
1.1 Immune System
The immune system is an organization of cells and molecules which protects the body against
infections. Because pathogens can rapidly evolve they can parry the host defense by develop-
ing resistance or being not detected. However, various immune mechanism have also evolved
in order to recognize and eliminate the new pathogens. Even very simple organisms such as
bacteria have a defense system consists of enzymes that protects against phage infections [1].
Yet, the mammalians and other higher organism have a much more complicated mechanism
called immune system which involves various cells, compounds and interactions. In mam-
mals, the immune system protects the body from surface to interior as layers of protection.
The first layer, skin forms a physical barrier to prevent bacteria and viruses from entering
the body. The mucosal immunity is also belonged to first barrier of immune system. Mucus
covers the largest area of the epithelial surface of body and eliminates gut or respiratory
pathogens [2]. If pathogens survive the first barrier, the innate immune system detects and
forms a quick response in order to activate mechanism to kill and digest pathogens. In-
nate immunity is evolutionarily one of the oldest defense mechanism found in all classes
of animal and plant life. Innate immune system can distinguish self and non-self cells by
recognizing specific pathogenic compounds. A baby’s and an old man’s innate immunity can
recognize same range of foreign molecules. [3]. When pathogen is not eliminated by innate
immune system adaptive immunity step in and activates various mechanism for recogni-
tion and clearance of pathogens. Only vertebrates have adaptive immune system. Unlike
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innate immunity, adaptive immunity cannot form a quick response. It takes 2-3 days for
immune cells to produce specific antibodies against pathogens. Adaptive immunity is also
called as acquired immune system. Immune system gains ability to detect new pathogens
by encountering with them. When, body is infected with the same pathogen again, immune
system forms a quick response because it remembers the pathogen specific antigens. A new-
born baby acquires adaptive immunity months after birth. [4] However, breast milk contains
ready-made antibodies which provide a passive immunity for infant. Passive immunity can
also occur when maternal antibodies are transferred to the fetus through placenta during
pregnancy [5,6]. For many years, innate and adaptive immunity has been considered as two
distinct mechanisms but recent studies of host defense against pathogens have demonstrated
that the generated adaptive response is dependent on innate responses. Especially, Toll-
like receptors(TLRs), the key elements of innate immunity have been shown to be have an
essential role in activation of adaptive immunity [7–10].
1.2 Innate Immunity
Innate immunity is the first line of defense mechanism that protect the host from infections.
It is also known as non-specific immune system because it does not develop immunity against
specific pathogens. Unlike adaptive immune system it does not provide long-lasting immunity
to the host and provides immediate response to the infection [10].
Innate immunity in vertebrates consist of anatomical barriers, secretory molecular and
cellular components. The epithelial surfaces, mucus and saliva form a physical barrier against
microorganism. Fluids secreted from our body generally contains antimicrobial chemicals.
For instance, fatty acids in sweat inhibit the bacterial growth. In tears, saliva and nasal se-
cretions there are lysozyme and phospholipase which can disrupt the cell wall and membrane
of the bacteria. Defensins and surfactants found in the lung track also have antimicrobial
activity. If microorganisms pass the anatomical barriers infection occurs and humoral factors
step in. Humoral factors play important role in the recognition of pathogen, inflammation,
migration of immune cells, killing pathogen and clearing pathogenic waste. Complement
system is one the major humoral factors. It may lead to increased vascular permeability for
recruitment of phagocytic cells, and lysis and opsonization of bacteria. Inflammation in the
infection site also activates coagulation system which can trigger clotting, increased vascular
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Figure 1.1: Overview of the diverse mechanisms activated during innate immune response
to pathogens. Image adapted from [11].
permeability, secretion of chemotactic agents for phagocytic cells and antimicrobial
molecules. Lactoferrin, transferrin, lysozyme are other antimicrobial humoral factors se-
creted by immune cells. The most important factors during infections are cytokines secreted
by immune cells, such as interferons and interleukins which help signaling between immune
cells. Also, interferons can limit virus replication by increasing p53 activity. Cellular barrier
in the innate immune system consist of neutrophils, monocytes, macrophages, mast cells,
natural killer (NK) cells and eosinophils. Neutrophils and macrophages can phagocytose
invading organisms and kill them intracellularly. NK cells kills pathogens by secreting cyto-
toxic molecules. Eosinophils secrete chemical mediators which are effective in killing certain
parasites. Multiple mechanisms used by innate immune system are depicted in Figure 1.1.
Inflammation on the infection site is very important for the migration and activation of im-
mune cells. It is initiated by pro-inflammatory cytokines released from macrophages after
recognition of pathogen. These cells present certain receptors termed pattern recognition
receptors (PRRs) on their surface, which can recognize common pathogenic molecules that
are distinguishable from host molecules. Those non-self molecules are known as pathogen-
associated molecular patterns (PAMPs). When PRRs on the cell surfaces interact with
PAMPs inflammatory pathways are activated [1, 10].
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1.3 Adaptive Immunity
Adaptive immunity a is a highly sophisticated defensive system against pathogens and found
in vertebrates. It is also known as acquired immune system because it develops new strategies
during infections. Unlike innate immune system, adaptive immune response forms very
slow (4-7 days), but it provides very long protection. Adaptive immunity is composed of
highly specialized processes initiated with the activation of innate immune cells by pathogen
recognition and presentation of digested pathogenic antigens by APCs. Three main classes
of APCs are DCs, macrophages and B-cells. APCs begin processing pathogenic antigen by
either phagocytosis or receptor mediated internalization of pathogen. After degradation of
foreign structures, small fragments of antigens presented on cell surface as complexed with
MHC class I and II molecules. Only professional APCs and certain activated epithelial
cells have express MHC molecules but many infected cells can present pathogenic antigens.
Secreted cytokines from innate immune cells and interaction from APCs initiate proliferation
of naive T-cells (see Figure 1.2). Activated T-cells either kill recognized pathogens or help
other cells to proliferate or activate them. T helper cells activates B-cells with matching
antigen by interaction and IFN-γ secretion. Activated B-cells multiply and mature into
antibody producing plasma cells. Then, released antibodies attach to the pathogenic antigens
and mark them. Last, those marked pathogens or infected cells are cleared killer cells such
as cytotoxic T-cell, macrophages and NK-cells. Activated B-cells during primary immune
response, can form memory B cells which are able to live for a long time and respond quickly
in the case of infection with same pathogen [10,11].
1.4 Cells of the Immune System
Immune response against pathogens is prevailed complex interactions and activities of the
diverse cells types. Primary lymphoid organs like the bone marrow and the thymus are the
sites of lymphocyte production and maturation. Immune cells circulate through the blood
and move to secondary lymphoid organs like the spleen and lymph nodes, where APCs
present antigens to lymphocytes [10].
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Figure 1.2: Innate response triggered by PRR-PAMP interactions induces and instruct adap-
tive immunity through proinflammatory cytokines and dendritic cell mediated antigen pre-
sentation to T-cells. Image adapted from [12].
1.4.1 Dendritic cells
Dendritic cells (DCs) are the most specialized antigen presenting cells, initiating both pri-
mary and secondary immune responses. The main function of DCs is to process antigens
and transmit the information to the T cells of the immune system, acting as a messenger
which links innate and adaptive immunity [10]. DCs are in an immature state with high
phagocytic capacity when they originate from hematopoietic bone marrow progenitor cells.
Once activated DCs migrate to lymph nodes were they interact with T-cells and B-cells to
initiate adaptive immune response. DCs have PRRs such as TLRs which makes them detect
danger signals [13] and become activated. During activation DCs leave their immature state;
becoming less phagocytic, producing cytokines and upregulating co-stimulatory molecules
such as CD86 which is required for T-cell activation [14].
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DCs are mainly present in tissues but rarely found in the blood circulation where they
constitute approximately 1 percent of the peripheral blood mononuclear cells (PBMC). Tis-
sues in contact with external environment are more likely to present DCs, such as skin and
the inner lining of the nose, lungs, stomachs and intestines. Humans have two subsets of
DCs in peripheral blood called myeloid (m)DC and plasmacytoid (p)DC. Phenotypes and
functions of mDCs and pDCs are incompletely described but some of their common and
contrary characteristics have been determined. mDCs are CD11c+ and major stimulators of
T-cells whereas pDCs are DC11c- and can produce large amounts of type I interferon upon
activation [15].
1.4.2 T lymphocytes
T cells are the critical components of the adaptive immunity. T-cell are originated from
haematopoietic stem cells in bone marrow but they complete their maturation in thymus.
The T cell receptor (TCR) is a highly specific molecule found on the surface of T cells and
responsible for recognizing antigen bound to MHC class proteins. TCR diversity is carried by
a series of gene rearrangement events in the thymus. T cells expressing a wide repertoire of
TCR undergo positive and negative thymic selection before completing their maturation [10].
In the positive selection, thymic stroma cells express MHC molecules and T-cells with TCR
that are able to interact with those MHC molecules properly selected. MHC interaction
provides surival signal during this step and T-cells with no survival signals die. Survived
T-cells migrate from cortex to the medulla of the thymus. In medulla (negative selection),
stroma cells express MHC/self-peptide complexes and T-cells which strongly interact with
those molecules receive apoptotic signals and die. Survived ones leave thymus as matured
naive T cells. When a naive T cell interact with an activated APC it differentiates into
effector cell of which there are several types. After a pathogen infection is cleared most of
the effector T-cells undergo apoptosis, but some of them survive as long-lived memory cells
which can form rapid immune response against same pathogen [10].
1.4.2.1 Cytotoxic T cells
The cytotoxic T-cells (also known as killer T cells) harbor pathogens and cancer cells. They
have the CD8 co-receptor in association of TCR on their surface which can bind to MHC
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class I:peptide complex. Upon activation they interact with target cells and release cytotoxic
effector molecules like perforin and granzymes [10].
1.4.2.2 T helper cells
T helper cells express CD4 co-receptor which can recognize MHC class II:peptide complexes
together with TCR. Upon TCR triggered activation, T helper cells differentiate into two
major subtypes of cells known as Th1 and Th2 [16]. Each subtype produce different cytokines
have distinct functions. Th1 helper cell facilitate eradication of intracellular bacteria and
protozoa through activation of natural killer cells and macrophages by IFN- γ secretion
whereas Th2 helper cells activate B-cells to produce immunoglobulins [17].
1.4.2.3 Regulatory T cells
During negative selection of in thymus, auto-reactive T-cells are not completely excluded and
move into circulation. Regulatory T cells (T regs) suppress the effector functions of those
auto-reactive T-cells through release of IL-10, and anti-inflammatory cytokine and TGF-
β [18]. T regs divide into two subtypes, naturally occurring and adaptive [19]. Naturally
occurring T regs are maturated in the thymus with immunosuppressive properties whereas
adaptive T regs differentiate from the naive peripheral T cells [18].
1.4.3 B lymphocytes
B cells are vital components of adaptive immune system. In mammals, they are formed
in bone marrow and complete their maturation here. B cells which leave bone marrow re-
circulate and populate in the spleen and lymph nodes. They present the B cell receptors
(BRC) on the surface, which can bind antigens. Self-reactive BCR carrying B cells are
also eliminated in the bone marrow. BCR is a membrane bound antibody composed of
a conserved shaft attached to cell membrane and a unique, randomly determined antigen-
binding site (immunoglobulin). Each B cell express unique BCR which can bind to only one
particular antigen. B cells become activated when two BCR are cross-linked by this particular
antigen. Then, as an APC, B cell process antigen and present the peptides as attached to
MHC class II molecules which attract a matching T helper cell. Cytokines secreted by T cell
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triggers complete activation of B cells. Activated B cells begin to multiply and mature into
soluble immunoglobulin (antibody) producing plasma cells. Released antibodies attach to the
matching antigens. Cells or pathogens marked with antibodies then cleared by complement
cascade or killer immune cells. TLR signaling or repetitive bacterial peptides may also trigger
B cell activation without T cell interaction [10,20,21].
1.4.4 Macrophages
Macrophages are produced by differentiation of monocytes in tissues. They are the first
cells which recognize pathogens and produce immune response. Macrophages are specialized
phagocytic cells which can ingest pathogens or attack with killer molecules. Macrophages
have role in both innate and adaptive immunity. When pathogenic compounds are recog-
nized through PRRs in a non-specific manner, macrophages become activated, increasing
surface area and becoming highly phagocytic. Macrophages present antigens of ingested
pathogens on their surface and can activate T cells. Also, upon activation macrophages
secrete chemokines and cytokines which can attract and activate other immune cells [10,22].
1.5 Cytokines
Cytokines are the main contributers of communication between immune cells. Various se-
creted cytokines have roles in triggering inflammation, activation and differentiation of im-
mune cells as well as suppressing immune response. Some of the cytokines are proinflam-
matory which are necessary for the initiation of immune response to recruit granulocytes
and lymphocytes. Other cytokines are anti-inflammatory and function in the inhibition of
inflammation and promotion of healing once the infection is secured [23]. Over-exuberant
immune responses may cause autoimmune and auto-inflammatory diseases and serious in-
jury. Therefore, anti-inflammatory cytokines are essential for the recovery of the body after
infections and injuries.
Tumor necrosis factor alpha (TNF-α) is mostly secreted by activated macrophages and
triggers local containment of infection. TNF-α secretion by macrophages on the infection site
induces increased release of plasma proteins into tissue, enhanced blood vessel permeability,
increased phagocyte and lymphocyte migration into tissue and improved platelet adhesion
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to blood vessel wall. Although TNF-α secretion is essential local containment of infection,
in certain bacterial infections in bloodstream, systemic release of TNF-α into the circulation
causes loss a significant volume of plasma and eventually to shock, known as septic shock [24].
Interleukins (ILs) are subgroup of cytokines which mediates activation, differentiation
and development of immune cells. IL-1β is mainly produced by blood monocytes and
macrophages as a potent mediator to immune response to infections and injuries. IL-1β
is one of the early cytokines released during infection and induces expression of other proin-
flammatory cytokines and activation of T-cells and macrophages [24]. IL-6 is another proin-
flammatory cytokine mostly released by T-cells, macrophages and endothelial cells. It has a
role in growth and differentiation of B-cells, acute phase protein production and fever [24].
Increased expression and secretion of IL-6 induces autoimmune and autoinflammatory con-
ditions in various diseases such as atherosclerosis [25], diabetes [26], Alzheimer’s Disease [27],
systemic lupus erythematosus [28], multiple myeloma [29], Behc¸et’s disease [30], rheumatoid
arthritis [31] and prostate cancer [32].
IL-12 (known as NK-cell stimulatory factor) is chiefly secreted by macrophages and
DCs. It activates NK-cells and induces differentiation of T helper cells into Th1-like cells.
Disrupted IL-12 production or functioning causes impaired IFN-γ production and Th1 re-
sponses [24]. Interferons (IFN) are large group of proteins which have various functions
in metabolism, such as anti-viral activity, modulating immune responses against viruses,
bacteria, parasites and tumor cells and promoting activation and differentiation of cells. In-
terferons (IFNs) are proteins made and released by host cells in response to the presence of
pathogens such as viruses, bacteria, parasites or tumor cells. They allow communication be-
tween cells to trigger the protective defenses of the immune system that eradicate pathogens
or tumors. They are mainly divided into two subclasses according to the their roles: Type I
IFN, Type II IFN. Type I interferons (IFN-α and IFN-β) are essential for protection against
viral infections , whereas type II interferon (IFN-γ) has roles against bacterial and parasitic
infections. IFN-α and IFN-β are secreted by many cell types especially pDCs and lympho-
cytes and stimulate macrophages and NK cells to elicit antiviral and anti-tumor responses.
IFN-γ is secreted by activated T-cells and NK cells, and function in the regulation of the
inflammatory responses in both innate and adaptive immunity. T helper cells produces
IFn-g to help macrophages kill the bacteria and to induce proliferation of B-cells and class
switching [24]. Extensive production of IFN-γ is associated with various autoinflammatory
and autoimmune diseases [33].
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1.6 Pattern Recognition Receptors
PRRs are primitive part of the immune system, which are essential for detecting invading
pathogens and initiating innate and adaptive immunity. PRRs are activated by PAMPs
present in microbial structures or by damage-associated molecular patterns (DAMPs) ex-
posed or released by damaged cells. PRRs are composed of multiple membrane-associated
and cytosolic receptor families. Toll-like receptors (TLRs) and C-type lectin receptors
(CLRs) are membrane associated PRR families whereas NOD-like receptors (NLRs), RIG-
I-like receptors (RLRs) and AIM2-like receptors (ALRs) are cytosolic ones. Recognition
of PAMPs by PRRs usually triggers the intracellular signal transduction cascades which
initiate expression of pro-inflammatory cytokines, chemokines and antiviral molecules [34].
On the other hand, ligand binding to some NLRs or ALRs may trigger clustering of re-
ceptor monomers, inducing formation of inflammasome complexes. Inflammasomes activate
Caspase-1 which induces expression of pro-inflammatory cytokines IL-1β and IL-18 [35]. Be-
cause a pathogen contains various PAMPs such as lipopolysaccharides (LPS), ssRNA and
ssDNA multiple PRRs can be activated simultaneously, causing crosstalk between different
receptors and cascades which can also affect the direction of the immune response [36].
1.6.1 Toll-like receptors
TLRs are PRRs that have been conserved from insects to mammals and essential molecules
that alerts the immune system against microbial infections. They are named for their sim-
ilarity to Toll which was firstly discovered as in the fruit fly Drosophila melanogaster as
a receptor required for dorsoventral axis formation in early development [37]. Later, Toll
was shown to have essential roles in fly’s immunity against fungal functions [38]. TLRs, the
mammalian homologue of Toll was identified in 1997, which was shown to actively induce
cytokine production and immune activation of T-cells [39]. Role of TLRs in recognition
of PAMPs discovered in genetic experiments which demonstrated that a mouse strain with
a missense mutation in the Tlr4 gene was resistant to LPS induced endotoxic shock [40].
Subsequently, many other TLRs recognized which can recognize diverse variety of PAMPs
derived from bacteria, viruses, protozoa and fungi. To date, 13 TLRs identified in mam-
malians, each recognizing unique PAMPs- table. Each TLR is composed of three regions: a
leucine-rich repeat (LRR) region mediating ligand-binding specificity, a transmembrane
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domain and a Toll/Interleukin-1 receptor (TIR) domain initiating intracellular signaling
pathways [64]. Most TLRs can recognize specific PAMPs by itself but there are certain
co-receptors augmenting receptor-ligand affinity, such as CD14 which cooperates with TLR4
for detection of LPS in the presence of Lipopolysaccharide-binding protein (LBP), a soluble
acute-phase protein that binds LPS [65].
TLRs are localized either on cell surface or on the membrane of cellular compartments.
TLRs are differentially expressed most cell types, especially immune cells. The cell types
which each TLR is expressed, and the cellular localization of them are summarized in Ta-
ble 1.1.
Upon activation, the TIR domain of TLRs can interact different adapter molecules in
cytoplasm such as Myleoid differentiation factor-88 (MyD88) and TIR-domain-containing
adapter-inducing interferon-β (TRIF), which may induce various signal pathways. TLR
signaling is divided into two distinct adapter dependent pathways, the MyD88-dependent
and TRIF-dependent (or MyD88-independent) pathway.
The MyD88-dependent signal pathway induced by ligand triggered dimerization of TLR
receptors, except TLR3. Activation of NFκB (nuclear factor kappa-light-chain-enhancer of
activated B cells) and mitogen-activated protein (MAP) kinase pathways is primarily induced
by MyD88. NFB is a very important transcription factor involved in control of diverse variety
of cellular actions such as stress induced and immune responses, developmental processes,
growth and apoptosis.
Activated MyD88 recruits kinases to trigger the signal pathway which eventually leads
phosphorylation and degradation of IκB (inhibitor of NFκB), allowing NFκB to diffuse into
cell nucleus and induce transcription of inflammatory cytokines [66].TRIF-dependent path-
way is utilized by TLR3 and TLR4 upon recognition of dsRNA and LPS respectively. TRIF
can activate certain kinases which initiate a branch of signal pathways which eventually lead
activation of NFB or interferon regulatory factor (IRF3) [66,67]. IRF3 is a transcription fac-
tor which enables production of type I interferons [68]. Depending on the circumstances and
the ligands, TLR activation can trigger signal pathways through different adapter proteins
but TLR 4 is the only one which uses all known four adapters. TIR mediated simultaneous
activation of different adapter signal pathways is necessary in certain conditions for produc-
tion of inflammatory cytokines [66]. The known adapters used by TLRs are represented in
Table 1.1 .
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As the importance of innate immunity for generation of adaptive immune responses was
indicated before [7–9], the key elements of innate immunity, TLRs are very important for
activation adaptive immunity. Therefore, using TLR ligands as adjuvants within human
vaccines may provide stronger and prolonged adaptive immunity [69]. Especially TLR7/8
and TLR9 ligands are very promising adjuvants due their presentation on immune-adaptive
immunity linking pDC surfaces [70]. Although, TLR7/8 ligands demonstrated great success
as vaccine adjuvantas against pathogens [71,72], TLR9 ligands (CpG ODNs) were reported
to be more effective for augmenting both humoral and cell mediated immune response [73].
Also, extensive variety of CpG ODNs with diverse and potent effects on immune responses
offers therapies against pathogens, autoinflammatory diseases and even cancer [74].
1.7 Immunmodulatory synthetic DNA motifs
TLR9 can discriminate self and non-self DNA and trigger immune response according to
the circumstance. Even though the stimulatory effect of bacterial DNA has been reported,
the DNA motifs in mammalian and adenoviral genomes have been shown to be immunosup-
pressive. Both stimulatory and suppressive synthetic DNA motifs are promising agents for
vaccine development and treatment of inflammatory conditions, respectively.
1.7.1 Immune stimulatory synthetic DNA motifs
In 1995, the immune stimulatory effects of unmethylated CpG motifs in bacterial DNA on
B-cells was demonstrated [75]. Later, it was discovered the recognition of bacterial CpG
motifs was mediated by TLR9 [57]. Although, the recognition mechanism of CpG motifs
by TLR9 is unclear, synthetic CpG ODN induced various responses depending on their
sequence, length and backbone. The immunostimulatory strength of different CpG ODN
may differ but they have been divided into three subclasses according to their structural
characteristics and impact [76].
 Type D ODNs (also known as class A) are characterized by a central palindromic
phosphodiester (PO) CpG sequence and PS-modified 3’ end poly(G) track. The poly
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G favors forms G-tetrad formation which provides higher molecular weight and subse-
quently high stability and increased endosomal uptake. D ODNs activates pDCs and
triggers IFN-α expression. They weakly stimulate TLR9-dependent NF-B signaling
and pro-inflammatory cytokine production [77–79].
 Type K ODNs (also known as class B) are 18-28mer(much larger than D-ODNs) mo-
tifs with a linear structure. They contain one or more 6mer CpG motifs with full
phosphorothioate backbone. K ODNs strongly activate B-cells and TLR9-dependent
NF-B signaling but weakly promote IFN-α expression. They are promising vaccine
adjuvants [75,79,80].
 Class C ODNs have characteristics of both K and D ODNs. They are composed of
a CpG-containing palindromic motif with full PS backbone. They can activate both
pDC and B-cells, also stimulate production IFN-α and pro-inflammatory cytokine [81].
1.7.2 Immunosuppressive synthetic DNA motifs
There are also synthetic DNA motifs which have immunosuppressive effects on immune
system in a TLR9-dependent or independent way. Inhibitory sequence motifs were firstly
described in DNA of adenovirus serotype [82]. Later, G-rich or methylated mammalian
DNA motifs suppressing CpG induced immune activation through NF-B and AP-1 induc-
tion were also reported [83–85]. Suppressive motifs were also determined in mammalian
telomeric sequences (TTAGGG) [86] and DNA of commensal bacteria [87]. After the discov-
ery of suppressive sequences, synthetic various ODNs were produced to reveal mechanism
and therapeutic potential. When immunosuppressive motifs were initially identified, they
were known to have ability to block CpG-induced immune activation. However, suppressive
ODNs were not inhibitors of CpG uptake [85] and they were shown to hamper multiple forms
of immune stimulation [88–91]. One of the most effective and studied suppressive ODN is
A151 which express multiple TTAGGG motifs, mimicking the immunosuppressive activity
of telomeric DNA [86]. The immunosuppressive effect of the A151 is connected to its G-
tetrad structure formed by Hoogstein binding of poly-G runs (Depicted in Figure 1.3). The
action mechanism of A151 is still unclear but it can down-regulate the production of proin-
flammatory and Th1 cytokines by inhibiting phosphorylation of STAT1/STAT4 [86, 92]. In
vivo administration of A151 demonstrated promising progresses against various pathogenic
conditions like autoimmune and inflammatory diseases in murine. [92–95].
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Disorders in immune system cause abnormal immune responses which give rise lethal
autoimmune diseases. The immune system attacks the body’s own cells and tissues, ending
up with tissue, organ damage. There is no accurate treatment for autoimmune diseases but
immunosuppressive are used to down-regulate immune response and avoid tissue damage.
Systemic lupus erythematosus (SLE) is an autoimmune disease which mostly harms the
heart, joints, lungs, blood vessels, liver, kidneys, skin and nervous system [96]. Intraperi-
toneal (IP) injection of A151 to female NZB/W mice (a useful model to study pathogenesis
and treatment of human SLE [97]) significantly decreased the severity of the disease and
prolonged the survival [95, 98]. Septic arthritis is another autoimmune disease caused by
joint infections by certain bacteria. It was reported that, both IP and intra-articular ad-
ministration of A151 significantly reduced inflammation and the swelling on the joint of
the CpG-induced septic arthritis murine models [99, 100]. Uveitis is a autoimmune disease
characterized by inflammation of uvea and IP or local administration of A151 successfully
reduced ocular inflammation in three differently uveitis induced murine models [95, 101].
Protective effect of A151 against inflammatory conditions such as lethal endotoxic shock
and acute slicosis was also demonstrated in mice [92,95].
As a result, A151 has a great potential as a immunosuppressive drug against diverse
pathological conditions , but its delivery in biological milieu is prone to digestion and serum
adsorption, leading
Figure 1.3: Representation of the G-tetrad structure of A151, formed through Hoogsteen
hydrogen bonding among G bases.
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to limited bioavailability, hampering its in vivo performance. Surely, phosphorothioate
chemistry makes A151 more stable for in vivo use in experimental animal models of
auto/inflammatory and auto-immune diseases, better delivery systems are required to unveil
its full potential.
1.8 Extracellular Vesicles
Intercellular communication is essential for all life forms, especially multicellular organism.
Communication between cells can be achieved by cell-to-cell contact, and transmission of
specific molecules. In last two decades, a new mechanism for intercellular communication
has been discovered that covers transfer of plasma membrane derived extracellular vesicles
(EVs). The release of apoptotic blebs during apoptosis was known long ago but the secretion
of membrane vesicles from healthy cells has recently demonstrated. Since then, EVs have
been isolated from nearly all types of mammalian cells, including stem cells, immune cells,
nerve cells and tumor cells. Intercellular communication through EVs were identified in not
only mammalian cells but in lower eukaryotes and prokaryotes. Until 1996 these vesicles
were initially regarded as membrane debris or waste containers with no real biological ef-
fect. However, Raposa et al. showed that extracellular vesicles could stimulate adaptive
immune responses [102]. Since then, many studies have demonstrated the significance of
EVs in intercellular communication via transfer of nucleic acids, lipids, cytokines and pro-
teins. As EVs have been isolated from cell culture medium of cell lines and primary cells
they have also been purified from most bodily fluids and the studies indicate that these
vesicles have a key role in not only the maintenance of physiological processes stem cells
but immune surveillance, tissue repair, blood coagulation, but also in the pathology causing
several diseases [103]. When the cell derived vesicles were identified, they were known to
be originated from cell membrane by direct shedding. Although, the term exosome was
firstly used for vesicles ranging from 40 to 1,000 nm the subcellular origin of these vesicles
was remained as secret until 1984 [104]. Then it has been determined that the release of
many nanovesicles during reticulocyte differentiation were outcome of multivesicular endo-
some (MVE) fusion with the plasma membrane [105, 106]. Currenty, these multivesicular
endosome derived nanovesicles(40-100 nm) are referred as exosomes, whereas the directly
shedded vesicles from plasma membrane (40 to 1,000 nm) are referred as microvesicles, ec-
tosomes, shedding vesicles or microparticles( [104, 107]). Distinct mechanisms of exosome
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and MP secretion are simply represented in Figure 1.4. The secretory mechanisms, function
and therapeutic applications of exosomes and microparticles (MP) are growing research area
in the field of physiology, immunology and genetics. However, there are controversial issues
about distanciation of those vesicles from each other. Current methods for exosome and MP
isolation (ultracentrifugation, filtering, sucrose gradient) are not able to separate MPs from
exosomes completely. MPs with the sizes in the range between 50-100 nm are also isolated
as mixed up with exosomes. Therefore, the function and actions of exosomes may not be
accurate. On the other hand, most of the previous studies did not deal with exosomes and
MPs separately, but experimented on mixed populations, spawning controversial data.
Figure 1.4: MPs are formed by directly shedding from the plasma membrane whereas, ex-
osomes are constituted in MVE and released through fusion of cell membrane and MVE.
Image adapted from [107].
1.9 Microparticles
Microparticles are small (40-1000 nm) vesicles shed from a variety of cells [108]. MPs were
termed as platelet dust when they were first identified by Peter Wolf during an ongoing
blood coagulation research in 1967 as a product of platelets [109]. Although MPs were
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initially thought to be useless cellular waste, decades of research focused on the tiny vesicles
have defined their roles as participators in thrombosis, cellular signaling, vascular injury,
homeostasis, inflammation and messengers in the transport of bioactive lipids, cytokines,
complement and immune signaling [108, 110–112]. Function of the MPs are dependent on
the derived cell type. However, distinct phenotypic subsets of MPs may have different
functions, even if derived from same cell type.
In circulation of healthy individuals, MPs were derived most abundantly from platelets
followed by red blood cells, leukocyte and endothelial cells [111,113]. MP amount, phenotype
in circulation altered by various diseases, such as atherosclerosis, diabetes, cancer, sepsis,
pulmonary hypertension and rheumatic diseases [114, 115]. For instance, platelet MPs are
increased in myocardial infarction [116], hypertension [117], diabetes [118] and cancer [119],
whereas endothelial MPs abundantly present in acute coronary syndromes [116] and Type 1
diabetes mellitus [120]. Diabetic patients have leukocyte originated MPs in their circulation
approximately threefold higher than healthy individuals [120]. Under different pathological
conditions, cellular origins and phenotypes of circulating MPs may shift (See Figure 1.5).
Since diverse phenotypes MPs are associated with various homeostatic activities, microparti-
cle research is an important emerging field focused on characterization of distinct phenotypes,
investigation of their formation mechanism and factors triggering their release and determi-
nation of their effects on pathogenesis of cardiovascular diseases or distinct inflammatory
conditions.
1.9.1 Microparticle formation
Unlike exosomes, MPs directly shed from the plasma membrane of the parent cell. The
mechanism behind MP formation is unclear but studies have suggested some factors have
role in MP formation, chop off mechanism.
Remodeling of the plasma membrane is essential for MP formation. Cell membrane bi-
layer has a specific lipid composition in inner and outer leaflets. Aminophospholipids (PS
and phospha-tidylethanolamine) are specifically found in the inner leaflet, whereas phos-
phatidylcholine and sphingomyelin are enriched in outer one. Localization and composition
of those factors are essential for the preserving plasma membrane asymmetry. The control of
lipid distribution on the transbilayer is carried by three transmembrane lipid transporters;
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Figure 1.5: The cellular origins and phenotypes of circulated MPs are affected by pathological
conditions. Image adapted from [121].
flippase, floppase and lipid scramblase [122]. Cell activation or apoptotis induction cause
significant and sustained increase of cytosolic Ca2+ which lead to the disruption of the mem-
brane asymmetry by enhancing scramblase and floppase activities and inhibiting PS specific
flippase. Especially, flippase inhibition is a very essential stage which cause exposure of the
PS, followed by cytoskeleton degradation by Ca2+- dependent proteolysis and lastly MP
release [123]. Because apoptotic or dying cells loose membrane asymmetry and secrete MPs
it is a problematic to distinguish whether they are derived from healthy or unhealthy cells
during in vitro culturing. In future studies, healthy cell MPs may be sorted out from the
others and better understanding of function and composition of MP subpopulations.
1.9.2 Microparticle composition
In comparison with exosomes, less is known about the protein and lipid composition of
MPs. Each MP have cytoplasmic and plasma membrane properties of the originated cell
however it is not clear whether they carry enriched particular components. If their secretion
mechanisms are clearly understood, more information about their content can be revealed.
Because composition of MPs is dependent on cell origin, any alteration on the cell effect
the MP content. Any environmental stimuli which make cell produce different proteins,
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mRNA, miRNAs also directly affect the MP composition. A general representation of MP
composition is depicted in Figure 1.6.
Each MP present specific surface membrane proteins based on their origin. For instance,
endothelial MPs have CD31 and CD146, whereas leukocyte MPs present CD4, CD3, or CD8
at their surface membrane [116, 124]. Thus, source of the circulating MPs can be detected
with cell marker Ab staining. Also, MP surface is phosphatidylserine(PS) enriched which
makes them bind to labeled Annexin-V and consequently detectable by flow cytometry [125].
Figure 1.6: Representation of MP composition. Surface of a MP is consist of molecules from
parental cell plasma membrane. Cellular origin and conditions affect the MP phenotype.
This representation does not reflect exact and complete content of MPs. Image adapted
from [123].
In addition to the cytoplasmic proteins, MPs also contains some mRNA, microRNA and
proteases of the parental cell [126–129]. Also a very recent study has revealed the presence
of genomic DNA fragments in MPs isolated from human plasma [130].
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1.9.3 Microparticle function
MPs are secreted by normal or activated cells as a consequence of differential environmental
effects. Therefore, MPs can been seen as pathways which exchange information between
cells. Because MPs carry mRNA, miRNA, transcription factors of the parent cell, they
can affect the transcription profile of the target cell [126, 127]. Microparticles can interact
with target cell through different mechanisms in order to mediate cell-to-cell communica-
tion. They can activate intracellular signaling by interacting target cell membrane receptors,
release their content into cytoplasm by fusing cell membrane, internalized through phagocy-
tosis, macropinocytosis or receptor-mediated endocytosis. Additionally, membrane proteins
presented on surface of microparticles can be cleaved by extracellular proteases and ex-
posed ligands can bind to target cell receptors to induce signal pathways [127, 131, 132](see
Figure 1.7). However, the physiological and pathophysiological roles of MPs are unclear.
Findings suggest that MPs have roles in inflammation, coagulation, vascular function, apop-
tosis and cell proliferation or differentiation [123, 133]. Especially, circulating MPs allows
membrane interactions between distant vascular cells.
Figure 1.7: Extracellular vesicles can transmit signals through their inside content or surface
proteins. The proposed mechanisms behind EV-mediated signal pathways are Receptor
binding, direct fusion with target cell plasma membrane, endocytosis and receptor cleavage.
Image adapted from [132].
MPs can be beneficial or deleterious depending on condition. Normally, MPs are trans-
ducers of biological information. MPs shed from activated macrophages can transmit inflam-
matory signals to foreign cells thus accelerate and strengthen immune responses [134](also
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see Fig 1.12). On the other hand, extensive secretion of MPs may cause significant proco-
agulation and inflammatory effects provoking adverse clinical symptoms in several vascular
diseases [133, 135]. Moreover, during some viral infections they may cause infection of viral
genetic information to foreign cells easily because they are considered as ”host” by other
cells [136]. Also, tumor derived MPs can suppress anti-tumor responses in favor of tumor
growth [137].
Role of the MPs in inflammation is one of the most popular research field currently. The
implications of MPs in inflammation has been reported by many studies. The most apparent
relationship is the elevated MP levels in various inflammatory conditions such as sepsis [138,
139], HIV and Ebola virus infection [140,141] and malaria [142,143]. Although, MP secretion
is enhanced during infections, stimulation with inflammatory cytokines such as TNF, IL-1,
IL-6 and type 1 interferons in the absence of infection also caused elevated MP secretion [144,
145]. As expected, both in vitro and in vivo administration of bacterial endotoxins induced
MP secretion in various cell types. For instance, apoptosis related MP secretion was observed
in LPS stimulated epithelial cells, whereas monocytes secrete MPs upon immune activation
[146–149]. Moreover, increased MP levels were reported in the circulation Plasmodium-
inocuated laboratory animals [150]. Especially platelet derived MPs in circulation have
significant roles in inflammation. Activated platelets secrete proinflammatory IL-1beta-rich
MPs which may favor atherosclerosis plaque formation [151,152]. Also, MPs secreted from in
vitro activated platelets enhanced expression of cell adhesion molecules and proinflammatory
cytokines in endothelial cells and THP-1 cell line [153]. On the line, leukocyte MPs in
circulation induced secretion of cytokines and expression of surface coagulation factors in
endothelial cells [154].
MPs have been suggested to have roles behind certain physiological immune escape mech-
anism. It was reported that, during pregnancy trophoblast release FasL bearing MPs to
induce T-cell death and subsequently escape from immune system despite its semi-allograft
properties [155]. Tumor cells such as ovarian cancer cells also may secrete FasL-bearing MPs
into the extracellular medium and cause apoptosis of lymphoid cells. Considering the fact
that normal ovarian epithelial cells do not secrete FasL bearing MPs, it is suggested that
tumor cells developed a mechanism that neutralize Fas-bearing immune cells which facili-
tate their escape from immune system [156, 157]. Another implication of MPs in immune
escape also reported in AIDS. CCR5 is chemokine receptor localized on the surface of white
blood cells and this receptor is used by many HIV versions to enter and infect the cell [158].
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Figure 1.8: Physiological effects and actions of MPs from different cellular origin. Image
adapted from [121].
MPs released from CCR5-positive cells rendered deficient peripheral blood mononuclear cells
CCR positive and thus susceptible to HIV-1 infection [159]. Another study also confirmed
the receptor transfer from CXCR4 positive platelets and megakaryocytes to CXCR4-null
cells through MPs [160].
It was reported that neutrophil derived MPs, termed extosomes may have potential roles
in opsonization due to their ability to efficiently bind opsonized bacteria and become adherent
to monocytic and endothelial cells [161,162].
Among countless significant physiological activities of MPs in human body, their role in
immune system is very diverse and essential. MP can remotely transport bacterial or viral
antigens via blood stream to APCs such as macrophages and DCs in the spleen without the
need for direct interaction with infected cells. Also, they can penetrate almost all tissues and
physiological barriers which cells cannot pass through and convey the signals. Such remote
interactions maintain a distance between site of infection and the site of immune induction,
also enhance the probability of early detection of infection. In certain circumstances MPs
can embrace parent cells assignment. For instance, TNF-stimulated, endothelial cell-derived
MPs can stimulate activation and maturation of pDCs [163]. Moreover, MPs secreted from
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Mycobacterium-infected macrophages were able to activate nave T cells by antigen present-
ing, thus rendering APC T-cell interactions unnecessary. Also, according to that study,
MPs were more effective than exosomes at inducing T-cell proliferation [164,165].
Additionally, elevated levels of MPs presenting CD4 antigen in circulation of human
immunodeficiency virus (HIV)-infected patients have been determined [140]. Enhanced lev-
els of MPs derived from activated leukocytes were observed in circulation in case of severe
trauma [166]. Also, in preeclampsia, granulocyte and lymphocyte originated MP subpop-
ulations significantly increased [167]. Almost every mammalian cell types are known to
be able to secrete MPs . Even smooth muscle cells release MPs which were suggested to
have potential functions in atherosclerosis and thrombus formation [121,168,169]. MPs may
have pleiotropic effects on the vascular wall in a consequence of their variety of subpopula-
tions. MPs act as vectors transmitting specific messages to other cells in regulating vascular
function and dysfunction depending on the donor cell type [121].
Mouse macrophage cell line secreted significantly higher amounts of MPs when activated
by various TLR ligands [170]. In the same study, a relevance between MP production and
nitric oxide (NO) release was reported and NO synthase inhibitors also greatly hampered MP
secretion [170]. NO is most commonly observed in monocytes and macrophages. Therefore,
it is plausible that each cell may have distinct mechanisms for MP production. Moreover,
same cell types may have different mechanism for producing subpopulations of MPs under
distinct conditions.
1.9.4 Microparticle immunotherapy
MPs are promising therapeutic tools for diverse applications such as vaccination, drug deliv-
ery, gene therapy due to their physiological structure. They can pass through every tissues
and be accumulated by cells rapidly. Unlike artificial vesicles, MPs are completely natural
and non-toxic. MPs from non-activated immune cells generally does not cause any im-
mune response in the recipient circulation, thus minimize the side effects. There are many
therapeutic agents which are effective in vitro studies but become impotent upon in vivo
administration. Absorption by serum or other tissues and degradation before reaching target
site hamper the functioning of those therapeutic agents. MPs are potential delivery systems
for those agents because of their cell membrane derived lipid structure. Also, MPs can be
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used for targeted therapies which also enhance the activity of the agents. MPs derived from
different cell types generally have distinct affinities to other cells. Choosing right MP type
may provide both protection and target specificity for therapeutic agents or drugs.
Because MPs conveys immunological signals between site of infection and immune in-
duction, they are suggested to be promising vaccination tools. Since, antigen carrying MPs
can effectively stimulate both innate and humoral responses, they can be used to increase
efficiency of adjuvants.
MPs may affect transcription profile of target cell by transporting mRNA, miRNA and
TFs [126]. Non-coding small RNA based therapies have shown great promise for many
diseases such as cancer [171]. However, their nucleic acid structure limits their bioavailability
in biological fluids. MPs are great delivery vehicles for such nucleic acid based therapeutic
agents.
Altering MP composition by genetically engineering of donor cell is another promising
approach in MP based therapeutics [172]. It has been reported that, MPs derived from
suicide gene mRNA transfected donor cells, were administered to schwannoma and success-
fully hampered tumow growth [173]. Several studies demonstrated that, mesenchymal stem
cell (MSC) MPs have MSC mimicking properties such as apoptosis inhibition, induction of
cell proliferation subsequent wound healing [174]. Thus MSC derived MPs are potential
therapeutic tools in regenerative medicine.
MPs are potential markers for early diagnosis of cardiovascular and other diseases by their
virtue of joining circulation from any site. Therefore, characterization of MPs from healthy
and unhealthy cells is essential to exploit their such property in future. There are some
studies carried out to use MPs as diagnostic tool for atherosclerosis vascular disease [175],
cancer [176] and smoking dependent lung damage [177].
1.10 Exosomes
Exosomes are small membrane vesicles with the size 40-100 nm. It is secreted from multivesic-
ular endosomes in most cell types including B cells [102], T cells, macrophages, DC [178],
mast cells, epithelial cells, platelets, reticulocytes, tumor cells. Moreover, exosomes and
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exosome-like vesicles have been isolated from various body fluids such as semen [179], blood
serum [180], urine [181], saliva [182], breast milk [183], amniotic fluid [184], ascites fluid [185],
cerebrospinal fluid [186] and bile [107,187]. Exosomes were initially described in 1983 in the
maturing reticulocytes [188, 189] and they become a significant target in immunology in
1996, when Raposo demonstrated the feature of B-cell isolated exosomes in stimulating T-
cells [102]. Since the Raposo’s milestone achievement in exosome history, the exosomes have
become an significant subject in antigen presentation and immune regulation. Although their
biological role has not been fully revealed yet, they have shown great success in therapeutic
approaches.
1.10.1 Exosome formation
Exosomes are formed in MVBs/endosomes of the cell which is a membrane-bounded com-
partment functioning as an intermediate in the degradation pathway of proteins either inter-
nalized from plasma membrane or transported from Golgi network [190]. Interestingly, the
secretion of exosome mechanism was demonstrated on a study about the iron-binding trans-
ferrin receptor by reticulocytes during maturation into erythrocytes in 1983 by Harding et
al. [188]. The down-regulation of transferrin receptors was considered as related to endocyto-
sis and lysosomal degradation and the visualization of colloidal gold-conjugated transferrin
accumulated by reticulocytes by electron microscopy suddenly reveled the multivesicular
bodies and their fusion with plasma membrane [188](see Figure 1.9).
Exosomes are formed by inward budding of the membrane of the MVB and released to
extracellular space after fusion of MVB with cell membrane [191]. Although these com-
partments share many elements, MVBs either fuse with lysosomes in lysosomal pathway for
degradation of their contents or fuse with plasma membrane for secretion of exosomes. These
two distinct fates rely on cholesterol proportion on MVBs. When cholesterol-rich MVBs are
in exosome secretory pathway, morphologically identical but cholesterol-poor ones are prone
to fuse with lysosomes [192].
Generation of exosomes in MVBs involves the lateral segregation of cargo at the delimiting
membrane of an endosome and inward budding and pinching of vesicles into the endosomal
lumen. Two mechanisms for exosome production have been identified so far; endosomal
sorting complex responsible for transport (ESCRT)-dependent and ESCRT-independent.
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Figure 1.9: Electron microscopy image of exosomes released by exocytosis of MVEs. Col-
loidal gold-conjugated transferrin were internalized by reticulocyte transferrin receptors and
enabled the visualization of such secretion mechanism by electron microscopy. On left, ac-
cumulated vesicle associated transferrins (Bar, 200 nm). Right, fusion of MVB with plasma
membrane and secretion of internal vesicles (Bar, 100 nm). Image adapted from [104,188].
There are four multiprotein complexes (ESCRT)-0, -I, -II, -III, which have specific roles in
the process of exosome formation; recognition and sequestration of ubiquitinated membrane
proteins at the endosomal delimiting membrane, budding and fission of intraluminal vesicles
(ILV) [194,195].(see Figure 1.10) ESCRT-independent exosome biogenesis and secretion has
been observed in oligodendroglial cell lines, which secrete proteolipid protein associated
exosomes. In these cell lines, cermaide-triggered budding take place, which is dependent
on a ceramide producing enzyme called sphingomyelinase [196]. Also, both ceramide and
ESCRT independent MVB formation was observed in pigment-producing melanocytes [197].
Specific membrane proteins including tetraspainins and CD63 (also a marker for exosomes)
were shown to have a role in ILV formation [198,199].
1.10.2 Exosome composition
The molecular composition of exosomes is dependent on the cell type of origin but most
exosomes contain highly concentrated certain molecules in common. Tetraspanins are the
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Figure 1.10: Exosomes originate from invaginating MVBs under control of complex events
and factors. ESCRTs, tetraspanins and the lipid ceramide are the essential molecules for
exosome formation. Also, a complex of SNARE proteins are most probably involved in
Membrane fusion and subsequent secretion of exosomes. Image adapted from [193].
most abundant protein family found on exosomes [201]. Tetraspanin is a highly conserved
membrane protein between species, which spans the membrane four times and act as scaf-
folding proteins, anchoring multiple proteins to a location on the plasma membrane [202].
The tetraspanins CD9, CD63, CD81, CD82 and CD151 are highly enriched on exosomes
in a similar was as lipid rafts [203]. Heat shock proteins have been identified in exosomes,
which are believed to have a role in proper protein folding. Integrins, cytoskeletal proteins,
subunits of trimeric G proteins are also found on exosomes. Transferrin Moreover, immune
cells derived exosomes contain specific proteins which have roles on immune regulation. B
lymphocytes, DCs, APCs, MCs secret exosomes enriched MHC class molecules, whereas
platelet and cytotoxic T cell derived exosomes contain von Willebrand factors [204] and
granzymes [205]. Killer proteins such as FasL and perforin have been identified on NK cell
derived exosomes [206]. Co-stimulatory molecules such as CD40, CD80 and CD86 are found
on the surface of the exosomes of APCs. Functional mRNAs and small RNAs including mi-
croRNAs are also found in the lumen of the exosomes [207]. Specific miRNAs are enriched
or reduced in the exosomes derived from different cell lines of same origin. Therefore,those
specific miRNAs and the mechanism behind selective sorting of miRNA into exosomes is an
important research area at the moment. A proposed exosome composition is depicted in
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Figure 1.11: A proposed structure of exosome with functional transmembrane and cytosolic
molecules. The indicated composition is not exhaustive and may differ depending upon
parent cell and stimulus. Image modified from [200].
Figure 1.11. Recent studies also reported that neural cells [208] and myoblasts [209] secrete
exosomes carrying mitochondiral DNA (mtDNA). Although the role of exosomal mtDNA has
not been identified yet, it has been suggested that it can reach target cell’s cytosol and be
imported into the mitochondria [210]. As another point, exosomes are specialized nanovesi-
cles with protective mechanism against complement lysis. For example, B cell exosomes
have been shown to contain glycosylphosphatidylinositol (GPI)-anchored regulators such as
CD55 and CD59 which provide protection against complement system [211]. Composition
of exosomes have gained importance as biomarkers or diagnostic tools for various diseases
such as renal diseases [212] ,Parkinson’s disease [213] and ovarian cancer [214] lately.
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1.10.3 Exosome function
Exosome secretion had been regarded as a random way of shedding waste substances until
their various functions were discovered in cell communication. Exosomes have important
properties such as small size, unique protein content and protection against complement ly-
sis, which makes them great signal or molecule carriers. Exosomes can transfer information
between cells in the form of proteins like the MHC:antigen complex or nucleic acids such
as mRNA and small RNAs. Although every aspect of exosomes have not been discovered
yet, they are considered as important mediators for various physiological processes. Like
microparticles exosomes interact with target cell through different mechanisms in order to
transfer signal and mediate cell-to-cell communication. They can activate intracellular sig-
naling by interacting target cell membrane receptors, release their content into cytoplasm
by fusing cell membrane, internalized through phagocytosis, macropinocytosis or receptor-
mediated endocytosis. Additionally, exosomal membrane proteins can be cleaved by extracel-
lular proteases and exposed ligands can bind to target cell receptors [127,215](see Figure 1.7).
Although exosomes have important roles in diverse physiological mechanisms, their function
in immune responses and their applications for therapeutic approaches are the most focused
research areas at the moment.
It has been shown that exosomes play an important role in regulation of immune responses
in both innate and adaptive immunity. Exosomes are involved in spreading of self and non-
self antigens to many sites of the body due to their small size. Exosomes which are secreted
from APCs such as B cells and DCs can activate T-cells by direct binding of exosomal MHC-
peptide complexes to the T-cell receptor [102,216–218]. Also, antigen bearing exosomes can
be internalized and processed by APCs, in order to activate T-cells [219]. Additionally,
the origin of the exosomes determine the impact, as mature DC exosomes induce T-cell
activation more effectively than immature DC exosomes [220, 221]. Moreover, exosomes
derived from mycoplasma infected DCs could induce both T-cell and B-cell proliferation.
Additionally, exosomes derived from mycoplasma infected DCs could induce both T-cell and
B-cell proliferation.
Exosomes are associated with various antigens according to the disease or infection type.
Pathogen-infected cell exosomes carry pathogen specific antigens, which can be processed
and associated by DCs to activate T-cells [222,223]. Furthermore, it has been demonstrated
that tumor-derived exosomes can also be processed by DCs and provide antitumoral immune
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Figure 1.12: The observed effects of extracellular vesicles on immune cell in vitro. a) Im-
munostimulatory actions of vesicles secreted from various sources. b) Inhibitory and sup-
pressive functions of vesicles derived from several cellular sources. Image adapted from [224].
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responses by activating T-cells through presentation of tumor specific antigens [225–227].
On the other hand, current studies demonstrate opposite effect of tumor-derived exosomes,
as mediating immunosuppressive responses in favor of tumor growth such as decreasing pro-
liferation of T-lymphocytes [137,228–230] and NK cells [231,232] or promoting differentiation
of repressive immune cells like Treg [233] and myeloid [234] cells. Current exosome isolation
methods are not able to differentiate exosomes from MPs completely. Therefore, small MP
subpopulations mixed with exosomes may be the reason behind such controversial results.
Microorganisms tend to exploit utilities of their host in order to reproduce and escape
immune system. In 2003, Gould et al hypothesized that exosome secretion pathways are
included in cellular trafficking of certain retroviruses [235]. For instance, HIV uses exosome
pathway for production of virions which have been shown to be assembled in MVBs and
secreted through exosomes. Exosomes derived from HIV-infected macrophages share same
phenotypes with healthy macrophage exosomes [236, 237]. In the light of those results, it
can be suggested that HIV uses same pathway with exosomes. In another study, it was
reported that immature DC derived exosome associated HIV can infect CD4+ T-cells and
interestingly they are 10 fold more infectious than free virus particles [238].
In contrast the general view of exosomes as immune stimulators, their role in immune
tolerance has been observed in growing number of studies. For instance, the prostate gland
epithelial cells secrete exosome-like vesicles known as prostasomes into seminal fluid [239].
It has been reported that prostasomes in semen protects sperms from the female immune
defense system by inhibiting NK cell function [240, 241]. Also, placental explants secrete
submicron sized vesicles which inhibit NK lymphocytes, possibly preventing immune re-
sponse against fetus [242]. In milk and colostrum, immunosuppressive exosomes with T-
cell inhibiting actions were identified [183]. Moreover, exosome-like vesicles present in the
bronchoalveolar fluid of the lung, bearing tolerizing molecules against allergens or causing
proinflammatory actions on airway epithelial cells [243]. Role of exosomes in the develop-
ment of immunological tolerance to orally fed antigens also reported. CD4+ T cells have
known to have crucial role in the induction of peripheral tolerance to non-self antigens orig-
inated from the microbial and dietary antigens in the intestinal lumen [244–246]. However,
the events behind the presentation of antigens to T-cells was unclear. It has been reported
that small intestinal epithelial cells process non-host antigens and release them into the
circulation as MHC class II-antigen complexes on surface of exosome-like vesicles, termed
tolerosomes [193,247].
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1.10.4 Exosome immunotherapy
Potential of exosomes as immunotherapeutic agents were first described in 1998 when tumor
growth in mice were reversed by injection of tumor peptide loaded DC exosomes [248].
Although producing humoral responses against tumor cells by using tumor-derived exosomes
is a promising study, there are concerns about tumor exosomes because of their potential
tumor growth favoring actions [229]. Therefore instead of direct administration of tumor
exosomes, they are pulsed onto ex vivo matured DCs [249].
Moreover, it has been reported that exosomes derived from heat stressed tumor cell can
chemoattract and stimulate DCs and T-cells more effectively than conventional tumor exo-
somes [250]. Currently exosome field is focused on immunotherapeutic application of DC exo-
somes (also called dexosomes) in various diseases such as cancer and autoimmune conditions.
A direct comparison between tumor exosomes and dexosomes revealed that dexosomes were
better stimulators of cytotoxic T-cells compared to tumor exosomes [251]. Loading of har-
vested dexosomes with tumor specific peptides provide promising anti-tumor response [252].
Peptide loaded DC exosomes demonstrated promising outcomes in two clinical trials con-
ducted with patients with non-small cell lung cancer and metastatic melanoma [253–255].
Additionally, exosomes have provided protection against microbial infections as prophy-
lactic vaccines. Antigen pulsed DCs have a great immunotherapeutic potential as source of
exosomes in the field of vaccination. For instance, Toxoplasma gondii pulsed DC derived ex-
osomes induced efficient and antigen specific Th1 response which provides protection against
toxoplasmosis [256]. Exosomes have great potential as inducers of humoral responses. In
various studies exosomes have been shown to induce protective immunoglobulin responses
against infections as vaccines [224, 257, 258]. Administration of exosomes from diphtheria
toxoid (DT) pulsed DC derived exosomes induced DT-specific Ig responses [257].
Although, exosomes have been generally studied as inducers of protective immune re-
sponses, they have also great potential against anti-inflammatory conditions. Exosomes
derived from adenovirus-transduced DC expressing IL-4 suppressed the inflammatory de-
layed type hypersensitivity reaction(DTP) and reduced the severity in the murine collagen
induced arthritis model by modulating the activity of APC and T-cells through a MHC class
II and Fas ligand/Fas dependent mechanism [259]. In same murine model, IL-10 treated or
fas ligand transduced DC derived exosomes also demonstrated similar inhibitory effect on
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severity of the disease [260,261]. Moreover, exosomes are potential anti-inflammatory drugs
carriers with in effective and targeted treatment inflammatory diseases. Exosomes carrying
curcumin, an anti-inflammatory agent were shown to deliver curcumin to specifically to ac-
tivated myeloid cells in vivo [262]. In another study, curcumin loaded exosomes have been
in treatment of brain inflammatory diseases in mice [263].
Together with, loading of various compounds and peptides to exosomes or treating cells
which are source of exosomes, the manipulation of exosome phenotypes is another promis-
ing application of therapeutics. Exosome display technology is one of the most novel and
advanced method for manipulation of exosome protein content. This technology enables the
tailoring of exosomes in production stage with new desirable properties through transfection
of cells [264] under favor of Lactadherin C1C2 domains localized on exosomes.
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Chapter 2
Aim of the Study
Extracellular vesicles (EVs) are membrane surrounded structures secreted by almost all cell
types, which are mediators of intercellular communication and involved in diverse biological
functions. Depending on their secretion mechanism and size, EVs are divided into two main
classes: exosomes and microparticles. Each EV has specific functions according to their
originated cell type and environmental stimuli. Despite their diverse roles in a large variety
physiological functions, immunomodulatory effect of exosomes and microvesicles in infections
and inflammatory conditions is in the spotlight of the EV studies. Determining the functions
of diverse EVs with distinct sources is essential to reveal their potential use in therapeutic
applications and diagnostics in diseases.
The aim of this study was to reveal potential role of micropartices in transmission of
pathogenic molecules in extracellular milieu during infection by testing immunostimulatory
properties of different TLR ligand associated microparticles on mouse splenocytes and human
blood peripheral mononuclear cells. Uptake and internalization of MPs by immune cells is the
phenomenon behind immunomodulatory actions of MPs, thus we aimed to reveal absorption
kinetics of distinct MPs by different immune cell. We also proposed to demonstrate protective
and conveying impact of MPs on DNA delivery by loading A151, a synthetic inhibitory ODN
to enhance its immunosuppressive effect in TLR triggered immune activation.
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Chapter 3
Materials and Methods
3.1 Materials
3.1.1 Immunomodulatory Agents
Table 3.1: Length and sequence of Synthetic ODNs.
ODN Brand Length Sequence
K-23 Alpha DNA (Canada) 12 mer 5‘-TCGAGCGTTCTC-3‘
A151 NIH (U.S.) 24 mer 5‘-TTAGGGTTAGGGTTAGGGTTAGGG-3‘
Table 3.2: List of TLR ligands.
Ligand Source Brand
LTA S.aureus Invivogen, USA
Zymosan S.cerevisiae Invivogen, USA
PGN B.subtilis Fluka, Switzerland
Poly(I:C)(HMW) Synthetic GE Healthcare
LPS E. coli Sigma
R848 synthetic Invivogen, USA
Bacterial DNA P. pentosaceus -
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3.1.2 ELISA Reagents
Table 3.3: Concentrations of ELISA coating Ab and Recombinant antibodies for Mouse.
Antibody Brand Coating Recombinant (starting)
TNF-α Biolegend 4 µg\ml 500 ng\ml
IL-6 Biolegend 2 µg\ml 1000 ng\ml
IL-12 Biolegend 4 µg\ml 500 ng\ml
Table 3.4: Concentrations of ELISA coating Ab and Recombinant antibodies for Human.
Antibody Brand Coating Recombinant (starting)
TNF-α Endogen 3 µg\ml 1000 ng\ml
IL-6 Endogen 4 µg\ml 1000 ng\ml
IFN-α MapTech 5 µg\ml 250 ng\ml
IFN-γ BD 10 µg\ml 500 ng\ml
3.2 Methods
3.2.1 Cytokine ELISA
For stimulation assays, cells(Splenocytes, PBMCs, RAWs) were counted and cultured into
96 cell culture plate wells equally (Generally 2x105 RAW cells and 4x105 splenocytes and
PBMCs per well in 100 µl RPMI1640 medium with 5% FBS). Then, stimulants were prepared
and added onto cells. Plates were incubated about 24 hours. During incubation of cells the
first two steps of cytokine ELISA were completed. High binding polysorp (Nunc, Denmark)
or Immulon 2HB plates (Thermo Scientific, USA) were coated with monoclonal antibodies
(50 µl/well) for O/N at +4Co. Monoclonal antibodies were prepared from stocks with
working concentrations by diluting with PBS. Then plates were incubated at RT for about 15
minutes. By rapidly turning upside down the plates, the unattached monoclonal antibodies
were discarded into sink. 200 µl of blocking buffer was added to each well in order to block
the naked surfaces. After 2-3 hours incubation blocking buffer was discarded and plates were
washed 5 times with washing buffer for 5 minutes incubation in each time. Then plates were
rinsed with ddH2O three times. By gently tapping to tissue papers, plates were dried. 50
µl of serial dilutions of recombinant cytokines (in PBS) and cell culture supernatant were
added and incubated 4 h at RT or o/n at +4Co . Plates were washed and dried. Biotin
conjugated antibodies were diluted in T-cell buffer with 1:1000 dilution factor (for 1λ stock).
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Streptavidin-AKP solutions were also prepared in T-cell buffer with 1:3000 dilution factor
and kept at +4Co. After 2 hours of incubation at RT, plates were washed and dried. 50
µl of previously prepared Streptavidin-AKP solution was added to each well. Plates were
incubated for 1 h at RT then washed and dried. PNPP (Thermo) substrate solution was
prepared according to the manual and 50 µl of it was transfered into wells. After color
formation was observed plates were read at ELISA reader (BioTek) at 405 nm with time
intervals. Used concentration of ELISA reagents are listed in Table 3.3 and 3.4.
3.2.2 NO detection by Griess Method
After in vitro stimulation assays conducted with RAW cell lines, plates were centrifuged at
400 g. 25 µl of cell culture supernatant was transferred to 96 well microtiter plates. 25 µl
of Griess Reagent (Sigma-Aldrich) was added onto each sample. After 15 min incubation
plates were read by Elisa Reader at 405 nm (BioTek).
3.2.3 Flow Cytometry
3.2.3.1 Fixation of Cells
After cell treatments of cells ended, cell were centrifuged and aspirated. Pellets were agitated
and 100µl of 4% parafolmadehhyde (Invitrogen, USA) was added while vortexing. Cells were
incubated 15 min at RT and then 2 ml PBS-BSA Azide (FACS Buffer; Appendix A) was
added. After cells were centrifuged and aspirated, the pellets were dissolved in 1 ml FACS
Buffer and stored at +4C(7 days at max) before further stainings.
3.2.3.2 Surface Marker Staining Cells
Fixed of live cells were centrifuged and supernatants were aspirated. Depending on the stain-
ing combinations, cells were separated into tubes (about 2 X 105 cells per staining). Live
cells should be worked on ice in order to maintain their viability. Pellets were suspended
in freshly prepared 100 µl FACS Buffer containing 1 µl/ml of fluorochrome conjugated anti-
bodies for specific cell markers and incubated for 30 min at RT in dark. 1 ml FACS Buffer
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was added and cells were centrifuged and aspirated. Pellets were suspended in 200 µl FACS
Buffer and transfered to 96-well U Bottom Plates, then analyzed on BD Accuri C6 Flow
Cytometer.
3.2.3.3 Apoptosis and Necrosis Detection: Annexin-V, PI Staining
Cells were washed twice with cold PBS then resuspended in 1x Annexin-V binding buffer at
a concentration of 2 x 106 cells per ml. 200 µl of the cell suspension was transferred to 1.5
ml tubes.
3.2.3.4 Surface Marker Staining of Microvesicles
Microparticles, apoptotic belebs and exosomes were transferred to 1.5 ml tubes and required
amount of fluorochrome conjugated antibodies (CD81, Annexin-V) and Annexin-V Binding
Buffer(1X final conc.) added at 1 µl/ml concentration in 100 µl. Microvesicles were inbu-
bated for 1 hour at RT in dark. 1 ml 1X Annexin-V Binding Buffer added and tubes were
centrifuged at 16.000g(Microvesicles and A.Blebs) or 150.000g(Exosomes) for 1 hour. Super-
natant was discarded and pellets were dissolved in Annexin-V Binding Buffer and analyzed
by flow cytometry.
3.2.4 Preparation of Single Cell Suspensions of Mouse Spleen
Cells
The spleens were removed from male C57BL/6 mice after sacrificing by cervical dislocation
and transferred to cold RPMI medium containing 2% FBS in 35x15mm cell culture petri
dishes. In order to obtain single cell suspensions, spleens were disrupted with sterile syringe
plungers by circular moves under lumen-air hood. Then all of the cells except the big scraps
collapsed to petri dishes bottom were transferred to 15 ml falcon tubes. In order to wash
cells, total volumes were completed to 10 ml with RPMI containing 2% FBS. The cells were
centrifuged at 1500 rpm for 5 min. The supernatants were discarded and the pellet gently
disrupted and homogenized with media. After one more wash step, cells were dissolved in
1 ml warm RPMI medium supplemented with 5% FBS. Cells were counted to be used in
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further experiments. (Hyclone, USA)
3.2.5 PBMC Isolation
Blood samples were transferred into 50 ml falcons. Empty falcons were filled with 15 ml
of histopaque. 22.5 ml of blood was slowly poured on top of each histopaque layer. The
histopaque and blood should not be mixed, therefore the falcons have to be tilted slightly
and immobilized. Samples were centrifuged at 1800 RPM for 30 min (The brake setting
should be off.). The supernatant was aspirated into 50 ml. Four different layers formed
consisting of plasma, PBMC and basophile containing cloudy buffy coat, histopaque and red
blood cells from top to bottom respectively. The buffy coat was carefully transferred to new
falcons avoiding contamination from other layers. 2% FBS RPMI medium was added till
reaching total volume of 50 ml and mixture was centrifuged at 1800 RPM for 10 min. Then,
supernatant was discarded without disturbing the pellet. Pellet was washed two times by
resuspending with 10 ml and centrifugation.
3.2.6 Maintenance of Cell Lines
3.2.6.1 RAW 264.7
RAW 264.7 (ATCC®, TIB-71) is an Abelson murine leukemia virus transformed mouse
macrophage cell line. Cells were cultured in RMI1640 media with 10% (thawing) or 5%
(sustaining) FBS. Subcultures were prepared by scraping after discarding culture medium.
Cells were washed with 5% FBS media and appropriate aliquots of the cell suspension was
added to new flasks.
3.2.6.2 EG-7
EG.7 (ATCC®, CRL-2113) is a specific cell line derived from EL4, a mouse lymphoma
cell line. EG.7 was stably transfected with pAc-neo-OVA which carries a complete copy of
chicken ovalbumin (OVA) mRNA and neomycin (G-418) resistance gene. Cells were cultured
in RPMI1640 media with 10% (thawing) or 5% (sustaining) FBS and supplemented with
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with 1mg/ml G-418 (Hyclone). Culture maintenance was performed by refreshing the media
in every 2-3 days. In order to avoid clumping of cells media was suspended everyday by
pipetting up and down.
3.2.6.3 NIH-3T3
NIH/3T3 (ATCC®CRL-1658) is a mouse embryonic fibroblast cell line which is very useful
in DNA transfection studies. Cells were cultured in DMEM-HG media with 10% FBS. Cells
should not exceed 80% confluency. For subculturing, cell culture medium was removed and
cell layer was briefly rinsed with warm sterile PBS(HyClone, USA) in order to remove all
traces of serum which contains trypsin inhibitors. 1 ml of 0.25% Trypsin-EDTA solution is
added and incubated at 37C for 5-10 min. In order to avoid clumping cells should not be
agitated by hitting the flask during this step. 9 ml complete medium was added and cells
were centrifuged. Supernatant was discarded and pellets dissolved in fresh medium by gently
pipetting. Appropriate aliquots of the cell suspension was transferred to new flasks.
3.2.6.4 Jurkat
Jurkat, Clone E6-1 (ATCC®TIB-152) is a human T lymphocyte cell line that are used
to study acute T cell leukemia, T cell signaling. Cells were cultured in complete RPMI1640
medium with 10% FBS as suspensions. For subculturing, fresh media addition or medium
replacement is required. Cell cultures should be maintained at a cell concentration between
1 X 105 and 1 X 106 viable cells/ml. Culture medium should be renewed every 2 or 3 days.
3.2.6.5 CAL-1
CAL-1 is a plasmacytoid dendritic cell line established from a blastic natural killer cell
lymphoma patient. Cells were cultured in RPMI1640 media with 10% (thawing) or 5%
(sustaining) FBS. For subculturing, fresh medium addition and replacement is required. In
order to avoid clumping, cell medium should be suspended every day. A subcultivation ratio
of 1:5 to 1:10 is recommended in every 3-4 days.
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3.2.6.6 HT-29
HT-29 (ATCC®HTB-38) is a human colon adeno carcinoma cell line. Cells were cultured
in DMEM-HG media with 10% FBS. For subculturing, cell culture medium was removed and
cell layer was briefly rinsed with warm sterile PBS(HyClone, USA). 1 ml of 0.25% Trypsin-
EDTA solution is added and incubated at 37 ◦C for 5-10 min. 9 ml complete medium was
added and cells were centrifuged. Supernatant was discarded and pellets dissolved in fresh
medium by gently pipetting. Appropriate aliquots of the cell suspension was transferred to
new flasks.
3.2.7 Microvesicle Isolation
In order to get rid of cell debris the cell culture supernatants were collected into 15ml or
50ml falcon tubes and centrifuged at 500g for 10 mins at 4 ◦C. Supernatants were transferred
to new falcon tubes without disrupting the pellets and centrifuged at 1500g for 10 mins at
+4 ◦C. Supernatants were transferred to new falcon tubes. Falcon tubes were put into liquid
nitrogen and then transferred to −80 ◦C freezers. If the microvesicle isolation is carried on
same day, cell debris free supernatants can be kept at +4 ◦C for a few hours.
3.2.7.1 Microparticles and Apoptotic Blebs
Cell debris free cell culture supernatant was thawed in warm water. Extensive vortexing
was applied in order to separate clumped microvesicles. Supernatant transfers were carried
under laminar-air hood in order to avoid contamination. Supernatant was transferred to
sterile ultracentrifugation tubes and centrifuged at 16.000 g for 1h. After centrifugation,
supernatant was transferred to new falcon tubes for exosome isolation and the pellet were
dissolved in high volume cold PBS and again centrifuged at 16.000 g for 1 hour. Supernatant
was discarded and ultracentrifuge tubes were left upside down for 5-10 minutes for air dry.
Pellets dissolved in sterile cold PBS(HyClone). After counting microparticles were preserved
at −80 ◦C as aliquots.
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3.2.7.2 Exosomes
To isolate exosomes microparticle free supernatants were transferred to ultracentrifuge tubes
and centrifuged at 100,000g for 90 mins. Supernatants were discarded and pellets were
dissolved in large volumes of cold PBS and centrifuged at 100,000g for 90 mins. Supernatants
were discarded and tubes were left upside down for 5-10 minutes for air dry. Pellets dissolved
in sterile cold PBS. After counting exosomes were stored into -80C freezers as aliquots.
3.2.7.3 CFSE Staining and Quantification of Microvesicles
50 µl of isolated microvesicles were mixed with previously prepared 50 µlM CFSE (Biole-
gend,US) dye with 1:1 ratio and incubated 30 min at RT. Then for quenching, samples were
diluted 15 times with ice cold RPMI1640 medium containing 10% FBS. Tubes were cen-
trifuged and pellets were gently dissolved in cold 0.5% BSA-PBS gently. 20 µl aliquots were
taken and 1:40, 1:80, 1:160, 1:320 dilutions were prepared with PBS in 96-well U bottom
plates as duplicates. Microvesicles were counted on BD Accuri C6 through FL1 channel(FSC
threshold: 5000). It is very difficult to analyze too dense and too diluted samples. There-
fore, the two serial dilutions that have 2:1 ratio were taken as references in order to calculate
total vesicles. In Figure 3.1 there is an example analyze of CFSE stained RAW 264.7 derived
vesicles. The best fitting dilutions (40-80) were taken as references (Figure 3.2)
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Figure 3.1: Quantification of CFSE stained microparticles with different dilutions.
Figure 3.2: CFSE positive microparticle countings. Reference counting were determined by
best fitting ratios between serial dilutions.
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3.2.8 SP-DiOC Staining of Extracellular Vesicles
Microvesicles or exosomes were completed to 1 ml and 1 µl of 1µg/ml aliquots of SP-DiOC
was added. After 30 minutes incubation at RT and dark the samples were completed to 30
ml and centrifuged at relevant speeds. The supernatant was discarded. Pellet was agitated
and suspended in PBS.
3.2.9 Atomic Force Microscopy(AFM)
After cells were washed and resuspended in cell culture medium, 20 µl of cells were transferred
into 980 µl isotonic cell counting in flow cytometer tubes. If cells are derived from mice spleen
1 drop of zapoclopin was added to each tube in order to puncture and eliminate red blood
cells. Tubes were vortexed and a volume of 50 µl was read by the flow cytometer. The chart
was set to FSS-C to SSC-C hight and cell population was gated. The number of dots in the
gated area was multiplied with dilution factor in order to find total cell number in 1 ml cell
suspension.
3.2.10 Binding & Uptake and Internalization Assays
Binding & Uptake and internalization studies were done by using either SP-DiOC and CFSE
stained microvesicles. SP-DiOC is a green fluorescent lyophilic dye which can stain vesicular
membranes. Stained MPs can either bind to the surface of the cells or be internalized.
Trypan Blue is a dye which can penetrate into dead cells and determine cell viability. It is
also used for quenching of extracellular fluorescence signaling. To determine the proportion of
internalized vesicles, extracellular vesicle fuorescence was quenched with trypan blue (0.01%
final concentration). Quenching with trypan blue was only done with live cells. Since dead
cells also acquire trypan blue, internalization fluorescence signal would be lost. To determine
binding & uptake and internalization fluorescence was measured before and after the addition
of trypan blue. CFSE is membrane permeable dye which covalently bind to proteins inside
and outside of the vesicles. CFSE stained MPs were incubated with spleen cells or injected
intraperitoneally. Depending on the incubation time, cells were fixed (isolated first for in
vivo) and stained with surface markers. Cells were analyzed for fluorescence with flow
cytometry.
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3.2.11 Association of TLR ligands with Microparticles
TLR ligands and microvesicles were mixed in desired concentrations in eppendorf tubes in a
total volume of 200 µl. The they were incubated for 30 min at 37 ◦C. Then, 1.3 ml PBS was
added into each mixture tubes were centrifuged at 16,000 g. Supernatants were discarded
and pellets were agitated. Required amount of PBS added for final concentration and tubes
were vortexed. During the association of TLR ligands with microparticles it was presumed
that 100% of ligands were linked to microparticles although about 1% percent association
was expected at the furthest. Used TLR ligands are listed in Table 3.2.
3.2.12 Cell Counting
3.2.12.1 Hemocytometer
After primary cells and cell lines were washed and resuspended in fresh medium(1 ml- 10
ml), small aliquots were transferred to 1.5 ml tubes and diluted (10 to 50 folds) with fresh
medium. Then 10 µl from diluted cells were dropped onto hemocytometer surface. In order
to count viable cells, before dropping the diluted cell suspension onto hemacytometer, 10 µl
of it was mixed with 10 µl Trypan Blue(HyClone) and then 10 µl from the mixture was used
for counting. Blue colored cells are apoptotic or necrotic cells.
3.2.12.2 Flow Cytometry
After cells were washed and resuspended in cell culture medium, 20 µl of cell solution was
suspended in 980 µl Isoton II Diluent Buffer in flow cytometer tubes. If cells are derived
from mice spleen 1 drop of ZAP-OGLOBIN II Lytic Reagent (red blood cell lytic agent) was
added to each tube in order to puncture and eliminate red blood cells. Tubes were vortexed
and a volume of 50ul was read by the flow cytometer, BD Accuri C6. The chart was set
to FSS-C to SSC-C height and cell population was gated. The total number of dots in the
gated area was multiplied with 1000 in order to find cell number/ml in cell suspension.
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3.2.13 Cargo Loading to Extracellular Vesicles
The microvesicles and A151 were mixed with the desired amount in 1.2 ml tubes. For
example, generally per 10ug of A151 , 2 million microvesicles were added. If there are more
than one sample, all mixtures volumes were equalized by adding sterile PBS. The caps of
the tubes were replaced with caps with holes. Mixture was frozen in liquid nitrogen and
loaded into freeze-drier and lyophilized o/n. Then 30 µl sterile ddH2O was added and
vortexed for 30 secs. Then samples were vortexed for 10 secs in every 5 minutes(repeated
5 times). Then sterile PBS added to finalize volume. If cargo is nucleotide based, the
samples were centrifuged and supernatant was analyzed with NanoDrop-1000(Thermo) in
order to determine loading efficiency. The general methodology about A151 loading and
further analysis is summarized in Figure 3.3.
3.2.14 Micro BCA Protein Assay
Standards were prepared in tubes as shown in Table 3.5. Serial dilutions (with 1:2 or 1:3
ratio for each dilution) of microvesicles were staged in tubes. 10µl from each standard and
sample dilutions were transferred to 96 well qPCR plates as duplicates or triplicates. Then
working reagent(WR) was prepared according to the number of total used wells(well count
X 10 µl). To prepare WR, 25 part MA, 24 part MB and 1 part MC solution were mixed.
10 µl of WR was added to each well. Plate was sealed and incubated 2h at 37 ◦C. Then
samples were analyzed with NanoDrop-1000(Thermo) by using Micro BCA Program in the
software.
Table 3.5: Standard Preparation for Micro BCA Protein Assay
Standard Name Standard Conc. (mg/ml) Diluent (PBS) Solute (BSA)
A 0.2 90 µl 10 µl (2 mg/ml)
B 0.04 160 µl 40 µl from A
C 0.02 80 µl 80 µl from B
D 0.01 80 µl 80 µl from C
E 0.005 80 µl 80 µl from D
F 0.0025 80 µl 80 µl from E
G 0.0012 96 µl 64 µl from F
Blank - 50 µl -
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Figure 3.3: EV isolation and A151 loading protocol.
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Chapter 4
Results & Discussion
The present thesis aims to characterize and investigate the immunological properties of
extracellular vesicles (EVs) secreted from various cell types. To reach this goal firstly, i)
microparticles, ii) apoptotic blebs and iii) exosomes were isolated and purified from super-
natants of various mouse and human cell lines. Next, in order to delineate the transmission of
microbial/pathogenic by-products associated onto EVs and also to investigate immunomod-
ulatory character of secreted EVs on naive immune cells in vitro stimulation assays were
conducted. Furthermore, upon injection, in vivo fates of EVs were analyzed. Finally, their
potential application as a drug delivery vehicle was explored.
4.1 Physicochemical analyses of the extracellular vesi-
cles
The size and shape analyses of the isolated vesicles were investigated under atomic force
microscopy (AFM). In Figure 4.1, 3D topography of EVs were demonstrated. The height of
exosomes and MPs were approximately 40 and 80 nm, respectively. In phase 2D topography,
as expected (Figure 4.2), it was clearly observed that MPs were much bigger than secreted
exosomes (Figure 4.1 and 4.2).
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Figure 4.1: 3D Topography of RAW derived extracellular vesicles. A) Exosome, B) MP
Figure 4.2: AFM photomicrographs of phase 2D topography of RAW derived exosomes(left)
and MPs(right).
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While diameter of exosomes varied between 50-200 nm, MPs size distribution was found
to be in the range of 200-500 nm. Since our AFM analyses procedure required sample
preparation to be in dry state, these investigations demonstrated that the topographic height
was lower and diameter was bigger than expected sizes with respect to exosomes‘ hydrated
forms.
In addition to AFM analyses, physico-chemical characterization of EVs was also inves-
tigated by dynamic light scattering (DSL) method. Of note, this analysis method allows
us to gather information of EV particles suspended in aqueous state, in addition to their
surface charge distributions. In order to determine zeta potential and size, exosomes were
suspended in PBS, and their hydrated sizes were determined to be ≈256 nm (Figure 4.3A).
As expected, the average zeta potential value of exosomes was found to peak around -29mV
(Figure 4.3B) strongly correlated with the biological membranes‘ zeta-potential, confirming
that our isolated EVs stem from plasma membrane based vesicles [265].
Figure 4.3: Zeta potential and size of the exosomes derived from RAW 264.7 cells. (A)Size
distribution by intensity. (B)Zeta potential distribution. Measurements were made by
Malvern Nano ZS.
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4.2 Uptake and Internalization studies with EVs
Previous studies demonstrated that EVs were taken up by target cells at a different rate and
level [266]. It is important to determine internalization kinetics of vesicles in order to reveal
possible mechanisms, different functions and understand the potency as a drug delivery
vehicles. If EVs from various cells are differentially taken up by distinct immune cells it
could be monitored by double labeling of these cells upon incubating them with labeled
EVs. For that internalization and uptake experiments were performed with SP-DiOC- a
green fluorescent membrane dye -labeled vesicles. Incubations of EVs and mouse spleen cells
were varied in these experiments (i.e. different EV:Cell ratios were used).
As seen in Figure 4.4, after 8h of incubation of EVs with RAW cells, apoptotic exosomes
demonstrated the maximum rate of uptake by spleen cells. Exosomes derived from apoptotic
cells demonstrated the highest uptake whereas normal exosomes indicated the lowest value.
Also, uptake of the apoptotic blebs were greater than MPs. The uptake of apoptotic EVs
was an unexpected observation. Both MFI and SP-DiOC signals at cell:EV ratio of 1:64 the
top highest binding was observed with apoptotic EVs.
While binding is a critical step for vesicle interaction with the target cells, internalization
of that bound vesicle is also important. Figure 4.5 summarizes the findings of the studies
on internalization. In order to detect internalization of vesicles, cells were stained with
Trypan Blue (TB) after incubation with SP-DiOC labeled EVs (see Section 3.2.10 for details).
Consistent with the results in Figure 4.4, apoptotic exosomes entered into cells (at 1:64
cell:EV ratio) significantly higher than other vesicles . Again, apoptotic blebs internalized
slightly better than MPs. While 80% of the spleen cells were positive for apoptotic exosome
signal by 8 h, only 10% was bound on the surface and 70% were internalized. Strikingly,
for apoptotic blebs, and other EVs the degree of internalization was not as impressive as
apoptotic exosomes. For apoptotic blebs 50% of spleen cells were positive for SP-DiOC signal
(Fig 4.4) but only 15% of spleen cells internalized these blebs after 8h of in vitro incubation
at 1:64 ratio (please compare Fig 4.4A vs Fig 4.5A yellow line).
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Figure 4.4: Uptake of RAW derived different EVs by mouse spleen cells. SP-DiOC labeled
EVs incubated with splenocytes at different EV:Cell ratios for 8 hours and cells were analyzed
with flow cytometry for SP-DiOC signal. A) Percentage of SP-DiOC positive cells, B) Mean
fluorescence intensity (MFI) values. A: Apoptotic forms of EVs
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Figure 4.5: Internalization of RAW derived different EVs by mouse spleen cell. SP-DiOC
labeled EVs were incubated with splenocytes with different EV:Cell ratios for 8 hours. Before
analyzing cells were stained with Trypan Blue. A) Percentage of SP-DiOC positive cells, B)
Mean fluorescence intensity (MFI) values. A: Apoptotic forms of EVs
A similar experiment with more time points were planned to distinguish the level of
binding and internalization kinetics of EVs at two different cell:EV ratio. Data revealed that
RAW derived MPs internalized more rapidly than exosomes and apoptotic blebs (Figure 4.6)
within spleen cells. The binding to and internalization by cells increased as the EV ratio
increased from 1:4 to 1:16 at early time points (2 or 4h), but subsided at late time point
(8h incubation). Interestingly, binding of MPs reached 20% positivity (@ 1:4 ratio) by 2h of
incubation, but when MP ratio was used at 1:16, the cells bound > 45% of vesicles. At the
end of 8h incubation, MPs were increasingly taken up by cells at low cell:MP ratio, wheras,
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at 1:16 cell:MP ratio it was saturated (Figure 4.6A). Internalization kinetics of EVs by spleen
cells showed slightly different profile compared to uptake data. As seen in Figure 4.6A, all
EV types progressively bound to spleen cells as the incubation time prolonged irrespective
of cell:EV ratio, however, internalization of EVs by immune cells increased and peaked at
4h post-incubation and by 8h the levels either dropped or remained unchanged for all EV
types at both Cell:EV ratios (Figure 4.6B).
Figure 4.6: Uptake and Internalization kinetics of RAW derived normal and apoptotic vesi-
cles. SP-DiOC labeled exosomes, MPs and A.blebs were incubated with mice spleen cells for
2, 4 and 8 hours with two different concentrations. A) Uptake of vesicles. B) Internalization.
A.bleb: Apoptotic Bleb
4.2.1 Influence of cell source of EVs on binding and internalization
by spleen cells
It is a known fact that different cells secrete EVs at different amount and rate depending on
that specific cell‘s physiological state. These EVs do regulate different biological processes
upon internalization by target cells. So far in this study we demonstrated that macrophage
derived extracellular vesicles do enter into different cells at a different rate and level, but we
have never compared different cell secreted EV entry on target cells.
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Figure 4.7: Uptake and Internalization kinetics of RAW and EG-7 derived normal and
apoptotic vesicles. SP-DiOC labeled MPs and A.blebs were incubated with mice spleen cells
for 2, 4 and 8 hours. Cell:EV ratio is 1:16. A.bleb: Apoptotic Bleb
To understand whether different cells that secrete their EVs differentially internalized
by a target cells, EVs from EG-7 and RAW cells were purified and their binding and inter-
nalization kinetics were tested on spleen cell culture. Similar to previous section Cell:EV
ratio was kept at 1:16, and incubation time was continued up to 8 h. As seen in Figure
4.12, while uptake kinetics for both EV sets showed similar trend irrespective of EV type,
internalization kinetics was slightly different. RAW derived EVs (MP and Apoptotic blebs)
at earlier time points internalized by spleen cells much faster than EG-7 EVs. There were
2 fold more RAW EV positive cells at 2h, compared to EG-7 positive spleen cells. This
difference was lost by 8h and both EG-7 and RAW EVs internalized at similar levels ( 30%
cells were positive for EVs irrespective of cell source, Fig. 4.7).
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4.2.2 Studies on differential internalization of EVs by immune
cells
After establishing that immune cells do take up secreted EVs and internalize them differ-
entially, we wished to identify the cell types internalizing these vesicles. Of note, in our
previous experiments EVs were labeled with the lipophilic dye SP-DiOC, but this dye could
not be compensated during cell specific staining procedure, so for these experiments we had
to shift to another fluorescent dye known as carboxyfluorescein succinimidyl ester (CFSE).
CFSE can be retained within vesicles for extremely long periods due to its covalent bond
between succinimidyl groups and lysine resides of vesiclular molecules. Also, once it was
incorporated within vesicles, it cannot be transferred to adjacent vesicles unless they fuses.
CFSE labeled MPs from mouse i) macrophage (RAW), ii) T-cell (EG-7) and iii) fibroblast
(NIH-3T3) cell lines, were incubated with spleen cells (@ 1:8 ratio for up to 16 h). Inter-
nalization kinetics by each immune cell types: i) B cells (B220+), ii) T-cells (CD+), iii)
Macrophages (CD11b+), and iv) Dendritic Cells (CD11c+) were studied by FACS against
each cell-specific surface marker by florochrome conjugated antibody. By 16 h of incubation
of different EVs isolated from different cells it was found that over 30% of spleen cells took
up NIH-3T3 MPs this was followed by EG-7 and RAW MPs (Figure 4.8). Interestingly,
EG-7 MPs were taken up by more cells according to the RAW MPs which was exactly
Figure 4.8: Internalization of CFSE labeled RAW, EG-7 and NIH-3T3 MPs to mouse spleen
cells. CFSE-MPs were incubated with mice splenocytes in vitro for 1, 2, 4, 8, 16 hours.
Cell:MP ratio was 1:8. Then cells were analyzed for CFSE positivity by flow cytometry.
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opposite in previous SP-DiOC labeled internalization experiments. This is another example
to demonstrate that the dye used to label MPs may impact the outcome of the experiment.
4.2.2.1 MP Internalization by B cells
Total B cell ratio among spleen cells did not affected by vesicle treatment (Figure 4.9). When
CFSE positive cells were gated, to B cells, 90 % was positive for NIH-3T3-MP, 85 % for EG-7
and 70 % for RAW MPs within 16 hour. Entry kinetics of CFSE+ MPs to B220+ cells was
as follows: NIH-3T3 > EG-7 > RAW.
Figure 4.9: Analysis of internalization of MPs to B cells specifically. Cells incubated with
CFSE-MPs were fixed and stained with B220-APC Ab. For more details see also Fig 4.8.
4.2.2.2 MP Internalization by Splenic T-cells
Contrary to B-cells, T-cells does not readily took up MPS. The level of MP accumulationwas
in the range of 3-5% of all T-cells for the entire incubation period(Figure 4.10). T-cellsmostly
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took RAW MPs (Figure 4.10, top right panel) for the entire incubation period (1-16h). For
RAW MPs uptake, T-cell ratio among CFSE+ cells decreased by time indicating that, the
rate of early entry of MPs by T-cells at the onset of incubation was much faster than
late stages of incubation. Opposite to what was seen for B-cells, NIH-3T3 cells were least
internalized by T-cells at early incubation times, it did recover by 16 h of incubation. CFSE
positivity among T cells demonstrated that EG-7 MPs reach the highest accumulation at
2nd hour of incubation and then began to subside.
Figure 4.10: Analysis of internalization of MPs to T cells specifically. Cells incubated with
CFSE-MPs were fixed and stained with CD3-PE Ab. For more details see also Fig 4.8.
4.2.2.3 MP Internalization by Splenic DC-cells
Total DC ratio in mouse spleen ranges between 1 to 2% of all spleen cells. Upon MP
administration very small accumulation was observed between groups. When CFSE+ gated
DC cells were examined, MP + ratio was around 22% for RAW MPs and 5% for EG-7 and
NIH-3T3 MPs at 1st hour (Figure 4.11). Interestingly, at the end of 16th hours, DC ratio
in CFSE+ cells was around 10% for RAW, 4% for NIH-3T3 and 2% for EG-7 MPs. This
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significant decrease, points out the existence of differential internalization kinetics of various
microparticles. By 16h, CFSE positivity among DCs was around 70% for RAW, and NIH-
3T3 and 20% for EG-7 MPs which suggests that macrophage and fibroblast derived MPs
internalized by DCs significantly higher than T-cell MPs (Figure 4.11 lower left panel).
Figure 4.11: Analysis of internalization of MPs to DCs specifically. Cells incubated with
CFSE-MPs were fixed and stained with CD11c-PE Ab. For more details see also Fig 4.8.
4.2.2.4 MP Internalization by Splenic Macrophages
Internalization of RAW MPs by splenic macrophages was above 35% for the entire experi-
ment duration (Figure 4.12, upper right panel). Interestingly, NIH3T3 and EG7 cells inter-
nalized within macrophages far lees than RAW MPs (less than 10% of macrophages took up
these cells. significantly increased the macrophage ratio (Figure 4.12). CFSE positivity in
macrophages rose from ≈ 10% (at 1 h) to > 70% (at 16 h) for RAW MPs, this value was only
40% for NIH3T3 MPs. Interestingly EG7 MPs never exceeded 10% in splenic macrophages
(Figure 4.12 bottom left panel).
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Figure 4.12: Analysis of internalization of MPs to macrophages specifically. Cells incubated
with CFSE-MPs were fixed and stained with CD11b-PE Ab. For more details see also
Fig 4.8.
4.2.2.5 Internalization of different MPs by ICAM-1 expressing splenic cells.
ICAM-1 (Intercellular Adhesion Molecule 1 or CD54) is a glycoprotein which is typically
expressed on endothelial cells and immune cells. After CFSE labeled MP administration
of spleen cells, CD54 positive cells were gated and analyzed for CFSE signal as a control
(Figure 4.13), since most of the spleen cells are CD54 positive. As expected, internalization
kinetics of different MPs by ICAM-1+ cells were parallel to total values obtained for the
whole spleen analyses (please compare Figure 4.8 with lower left panel of Figure 4.13).
Figure 4.14 and Figure 4.15 summarizes dot-plots of cell population specific associations
of different MPs after 8 and 16 h incubation, respectively. Figure 4.16 represents pie chart
distribution of MP treated CFSE positive cell ratios at 8 h. As clearly demonstrated in these
figures there are distinct affinities of various MPs for different immune cells. Strikingly, all
MPs types irrespective of their sources greatly internalized by B cells in comparison to other
immune cells. Very less proportion of EG-7 and NIH-3T3 MPs were taken by macrophages,
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Figure 4.13: Internalization of CFSE-MPs to CD54 surface protein presenting spleen cells.
Cells incubated with CFSE-MPs were fixed and stained with CD54-PE Ab. For more details
see also Fig 4.8.
DCs and T-cells. However, notable percentage of RAW specific MPs penetrated especially
to macrophages.
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Figure 4.14: Dot plots of different splenic cells positive for CFSE-labeled MPs at 8h. For
more details see also Fig 4.8.
,
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Figure 4.15: Dot plots of different splenic cells positive for CFSE-labeled MPs at 16h. For
details see Figure 4.17.
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Figure 4.16: Immune cell ratios among MP treated CFSE positive cells. RAW, EG-7 and
NIH-3T3 derived MPs were given to spleen cells in vitro. After 8 hours of incubation cells
were fixed and stained with specific cell markers. Cell:MP ratio is 1:8.
4.2.3 In vivo distribution of MPs upon intrperitoneal administra-
tion to mice
In vitro experiments with MPs and spleen cells demonstrated that vesicles enter into spleen
cells differentially. The fate of MPs upon in vivo injection was not explored in great depth.
the internalization kinetics was essential in order to harness MPs for therapeutic applica-
tions. We used CFSE labeled MPs from 3 different cell lines and injected intraperitoneally
to C57BL/6 mice (100 million particles /animal). After 24 hours, mice were dissected to
examine spleen, lymph nodes (LN) and peritoneal exudate cells (PEC). Flow cytometry
analysis on collected PEC demonstrated that RAW derived MPs internalize to 9.5% of cells
whereas 2.5% of PECs were CFSE positive after injected with either EG-7 or NIH-3T3 MPs
(Figure 4.17). As expected the CFSE signals were very small among spleen and LN cells
(data not shown). Consistent with in vitro data there was a differential internalization patter
for MPs isolated from different cell source. Fluorescence intensity analyses of harvested cells
indicated that, of three MPs types, RAW MPs were the highest among others in terms of
internalization. (Figure 4.18).
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Figure 4.17: CFSE positivity of PECs. CFSE labeled RAW, EG-7, NIH-3T3 MPs
(10x107/mouse) were administered to C57BL/6 mice intraperitoneally. 24 h later, cells
were recovered, and monitored by flow cytometry.
Figure 4.18: Mean fluorescence intensities (MFI) of PEC, Spleen and LN cells dissected from
MP treated mice. CFSE labeled RAW, EG-7, NIH-3T3 MPs were injected to C57BL/6 mice
intraperitoneally. After 24 hours uptake was monitored by flow cytometry analysis of cell
fluorescence intensity.
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Cell specific uptake was analyzed by staining spleen cells with specific cell surface marker
antibodies. As seen in Table 4.1, PEC macrophages took up nearly all MP post-24h injection.
Notably, PEC resident macrophages took up over 95% of CFSE signal independent of the
source of the secreted MP.
Taken together our findings implicated that MPs are potential nanocarriers and can be
internalized in vivo for further immunotherapeutic interventions.
Table 4.1: CD11b, CD11c, CD3, B220 cell population percentages among CFSE positive
cells. For more details see also Fig 4.17
RAW MP EG-7 MP NIH-3T3 MP
B-cell 0.5± 0.1 1.8± 0.5 0.3± 0.2
T-cell 1± 0.2 1.7± 0.2 0.2± 0.1
Macrophage 98.8± 0.5 96± 1.5 95± 1
DC 1.6± 0.0 3.4± 0.5 3.6± 3.4
4.3 EVs transmit TLR ligands to distant cells and in-
duce immune activation
Recent studies demonstrated that EVs are capable of mediating cell-to-cell communication
[267] during immune responses. We postulated that cells infected by microbes or upon
ingesting bacterial by products freely circulating in biological milieu subsequently secrete
EVs harboring different TLR ligands. The critical step is to distinguish whether these
secreted EVs reaches distant sites and contribute to the pronunciation of the ongoing immune
activation upon internalization by other naive (or uninfected) immune cells. To test this
hypothesis a preliminary experiment was designed. RAW cells were incubated overnight
with 3 µg/ml LPS. The next day secreted MPs were isolated, purified from the supernatant
and counted. These MPs were then incubated with freshly cultured RAW cells at a ratio of
1:1 (cells:MP number ratio). 24 hours after stimulation with MPs cells were harvested and
IL-6 secretion along with nitric oxide production was determined from the supernatant by
ELISA and Griess method, respectively. As seen in Figure 4.19, MPs induced appreciable
amounts of IL-6 and NO from RAW cells. This induction is dependent on the cargo since
empty MPs did not initiate any activation. This data along with the data presented in
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Figure 4.19 suggested that cell-derived extracellular vesicles might be non-immunogenic or
immunogenic depending on the state of that cell. It also implied that if a cell is exposed
to bacterial by-products (such as LPS a TLR4 ligand) it has the capacity to transmit this
ligand via its secreted extracellular vesicles to other neighboring cells and it is sufficient to
trigger an immune cascade depending on the associated ligand.
Figure 4.19: MPs secreted from LPS exposed RAW cells (LPS-MP) can transmit its ligand
to other cells and demonstrate immunostimulatory activity. RAW cells treated with 3µg/ml
LPS for o/n, were harvested and MPs. LPS-harboring MPs were transfered to a freshly
cultured cells at a 1:1 MP:cell ratio. The supernatant of these MP treated cells were collected
and assayed for IL-6 and NO production. Free LPS (0.001-5 µg/ml, 5x dil.) was used as a
standard control to compare stimulatory activity of LPS associated MPs.
4.3.1 Effects of EVs on murine immune system cells
Current studies supported that MPs may play a very significant role during infections. Acti-
vated T-cell MPs can activate macrophages or MPs from stimulated macrophage can trigger
naive T-cells [224]. Moreover, extracellular vesicles were reported to carry nucleic acids such
as mRNAs or miRNAs, and contribute immune modulation [268]. However, it is not clear
whether MPs have role in transportation or presentation of bacterial products. After this
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encouraging preliminary finding we planed to examine such function of microvesicles after
incubating RAW 264.7, CAL-1 and EG-7; a macrophage, a pDC and a T-cell representative
member of the cell lines, respectively with various TLR ligands. The following ligands were
used throughout this set of experiments: i) LPS, (TLR4L), ii) poly(I:C), (TLR3L), iii) PGN,
(TLR2/6), iv) Zymosan, (TLR2L), v) R848, (TLR7/8L), and vi) bacterial DNA, (TLR9L)
MPs purified from above mentioned cell lines were incubated with the ligands for 30
mins at 37 ◦C. They were washed to remove excess unassociated ligands and then used for
stimulation assays. These ligand associated MPs were then incubated with freshly cultured
RAW cells (Figure 4.20), or spleen cells (Figure 4.21) for 24h. Supernatants were saved for
NO, IL-6 and IL-12 detection by Griess method, or ELISA, respectively.
In this experiment, it is important to note that the associations of the ligands on to MPs
were considered to be 100%, and the concentrations of each ligand in induction experiments
were based on this assumption. Another important point to note thatthe pDC cell line CAL-
1 is a human cell line, the MPs from this cell was intentionally included in these experiements
to check the interspecies effect of secreted vesicles on immune activation.
As seen in Figure 4.20A, LPS treated MPs derived from all cells led to nitric oxide (NO)
secretion similar to free LPS. PGN treated MPs also induced slight NO production but
no IL-6 and IL-12 (Figure 4.20B,C). Interestingly, Poly(I:C) treated EG-7 MPs provided
NO, IL-6 and IL-12 secretion which is similar to the free Poly(I:C). Contrarily, Poly(I:C)
treated RAW and CAL-1 MPs did not cause any immune activation on RAW cells. Of note,
untreated EG-7 MPs were capable of NO production but it did not induce either IL-6 or
IL-12 secretion. Our results suggests that LPS can bind to the macrophage, pDC and T-cell
derived microparticles even after 30 mins of incubation and LPS bearing MPs provide an
immune activation on cells that did not have exposed to LPS. Another important observation
is that T-cell derived MPs have the ability to specifically present dsRNA to macrophages
and trigger their synergistic activation, since in our hands only poly(I:C) treated EG-7 MPs
stimulated NO, IL-6 and IL-12 production from RAW cells (Figure 4.20A-C).
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Figure 4.20: Immunostimulatory properties of MPs incubated with TLR ligands. RAW, EG-
7 and CAL-1 derived MPs were incubated with TLR ligands for 30 min at 37Co. Different
ligand associated 106 MPs were administered onto fresh RAW cells (2x105 cells in µl media).
After 24 hours of incubation supernatant were collected for A) Griess Assay, B) IL-6 and
C) IL-12 ELISA. MPs were incubated in 5 µg/ml LPS, PGN, Zymosan, R848, Bacterial
DNA and 100 µg/ml Poly(I:C). Stimulation concentrations: LPS(0.2 µg/ml), Poly(I:C)(20
µg/ml)), PGN(1 µg/ml), Zymosan(1 µg/ml), R848 (1 µg/ml), DNA (1 µg/ml).
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Ligand treated MPs showed much different responses when incubated with spleen cells
in vitro. Only R848 treated MPs stimulated both IL-6 and IL-12 production where zymosan
treated MPs activated IL-12 secretion (Figure 4.21. Although bacterial DNA itself induced
IL-6 and IL-12 production, MPs treated with DNA did not cause any activation. Spleen cells
are consists of various types of immune cells and PGN, Poly(I:C), LPS did not stimulate the
expression of inflammatory cytokines at detectable levels.
Figure 4.21: Immunostimulatory properties of MPs incubated with TLR ligands. RAW, EG-
7 and CAL-1 derived MPs were incubated with TLR ligands for 30 min at 37Co. Different
ligand associated 106 million MP were administered onto fresh spleen cells (2x105 spleen
cells in 200 µl). After 24 hours of incubation supernatant were collected for A) IL-6 and B)
IL-12 ELISA. MPs were incubated in 5 µg/ml LPS, PGN, Zymosan, R848, Bacterial DNA
and 100 µg/ml Poly(I:C). Stimulation concentrations: LPS(1 µg/ml), Poly(I:C)(20 µg/ml)),
PGN(1 µg/ml), Zymosan(1 µg/ml), R848 (1 µg/ml), DNA (1 µg/ml).
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When taken together (Figure 4.20 and Figure 4.21) our results suggest that circulating
MPs secreted from different cells, if they are exposed to freely circulating microbial products
even for a brief period are capable of adhering these ligands on their surface and could aid
transmitting these ligands to other distant cells. These MPs can interact and can be inter-
nalized by different immune cells albeit at different level (or kinetics) leading to differential
and synergistic immune activation. Our findings point out to a phenomenon that MPs could
contribute to the amplification or dissemination of the infection and could contribute to the
severity of ongoing infection in vivo. Of note, the possibility of differential MP internalization
by naive immune cells must be separately investigated in depth in the future.
4.3.2 Effects of EVs on human immune system cells
Lastly, in this thesis the attribution of MP mediated pronounced immune activation was
tested on human PBMCs. MPs derived from MEG-01 (megakaryoblast), Jurkat (T-cell)
and CAL-1 (pDC) cell lines were incubated with TLR ligands and washed to get rid of
unattached ligands. Notably, all TLR ligand treated MPS from different cell courses led
to IL-6 and TNF-α secretion from PBMCs (Figure 4.22). A similar trend was seen for
IFN-γ secretion via ligand associated MPs, except for R848-associated MPs. A much lower
interferon secretion was yielded by MPs compared to free R848. None of the MPs led to any
IFNa secretion. This is probably due to inability of the pDCs to internalize MPs. Consistent
with mouse data this experiment also support the finding that MPs differentially regulate
immune activation when they are associated with ligands of microbial world.
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Figure 4.22: MEG-01, Jurkat, CAL-1 MPs stimulate immune activation on PBMCs after
incubation with TLR ligands. 106 MPs were first incubated with TLR ligands for 30 min
at 37Co. Then MPs were washed and administered to human PBMC cells (2x105 cells
in 200 µl media).Supernatants from 24h culture were collected for IL-6, TNF-α, IFN-γ
and IFN-α cytokine ELISA. MPs were incubated in 10 µg/ml LPS, PGN, Zymosan, R848,
LTA, Bacterial DNA and 100 µg/ml Poly(I:C). Stimulation concentrations: LPS(1 µg/ml),
Poly(I:C)(20 µg/ml)), PGN(1 µg/ml), Zymosan(1 µg/ml), R848 (1 µg/ml), LTA(1 µg/ml),
DNA (1 µg/ml).
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4.4 Studies with A151 ODN loaded EVs
As mentioned in the Introduction Section, A151 is a single stranded short ODN derived from
mammalian telomeric repeats with a broad range of immuno- suppressive activities [86]. Al-
though A151 is a very promising drug against auto-inflammatory or auto-immune diseases,
upon in vivo administration it is prone to digestion and/or serum protein adsorption, ham-
pering it’s in vivo performance due to limited bioavailability [269]. We postulated that, EVs
could be utilized as a suitable nano-carrier to encapsulate A151 ODN thus, improve its in
vivo stability and immunosuppressive performance upon injection. In order to determine
whether EVs possess such potency as drug carriers, A151 was loaded into vesicles by one
of our Lab‘s patented strategy known as ”the rehydration-dehydration technology” method.
Then, EV internalization and uptake kinetics were determined. Also, various EVs loaded
with A151 administered to mice spleen cells simultaneously with different immunostimula-
tory TLR ligands and immunosuppressive potency with respect to its free A151 counterpart
were analyzed.
In the literature, there are various exosome and microparticle isolation and purification
protocols with different advantages and disadvantages. In this thesis, ultracentrifugation
coupled with filtration technique were performed (please see materials and Method, Sec-
tion 3.2.7). In our method, size is the only distinguishing feature between different particles,
and it permits us to sequentially separate microparticles from exosomes in a cell supernatant
pool. Therefore, MPs smaller than 200nm can interfuse with exosomes. In order to validate
that the isolated products are cell derived vesicles and are clean from any contaminating
cell debris, flow cytometry based characterization experiments were performed. Measuring
the protein content of EVs is a popular method for quantification. However, depending on
the cell type and physiological state including stress, or following different treatments on the
same cell may affect the protein content expressed on that same vesicles isolated at different
times from the same cell source. Therefore, in our studies we aimed to determine number of
the EVs as a quantification method. For this purpose, we selected flow cytometry method
to detect, quantify and characterize different extracellular vesicles from cell supernatants.
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4.4.1 CD81 Expression on EVs before and after reconstitution
The tetraspanin CD81 is a surface protein which is expressed in most cell types. Any cellular
vesicles which directly shed from the surface of cells should express CD81 on their surfaces.
However, exosomes are secreted from multivesicular bodies to extra-cellular space and they
are not expected to be positive for CD81 on their surface. Phosphatidylserine (PS) is a
phospholipid component which is usually found on the cytosolic side of cell membranes.
An enzyme called flippase keep the PS on the inner-leaflet but when cell dies or goes to
apoptosis, PS becomes exposed on the surface of the cell. Because there is no flippase action
in EVs they present PS on their surface and can be detected by Annexin V staining.
EVs isolated from mouse macrophage cell line (RAW 264.7) were stained with CD81-Ab
and Annexin V (Figure 4.23). A low CD81 positivity was observed in exosomes as compared
to the MPs whereas Annexin V positivity was high in all EVs, as expected.
It was unclear to distinguish whether A151 was loaded into vesicles or they adhered to
the EV surface. As a control, lyophilized and then reconstituted EVs without A151 loading
were also used. Reconstitution did not alter the CD81 expression on EVs,however, A151
loading caused increased CD81 and Annexin V positivity in exosomes and Apop. Blebs. We
repeated the same experiment by including an extra group, exosome-like particles derived
from apoptotic RAW cells (A. Exo). Normally, when cells undergo apoptosis they stop
producing exosomes [270] but the pellets centrifuged at 100.000 g were collected and added
to the experiment. While A151 loading did not effect CD81-Ab signal in exosomes, it did
slightly in apoptotic exosomes and MPs (Figure 4.24). Unexpectedly, when A. blebs were
loaded with A151, it significantly increased the CD81-Ab signaling. When we compare the
CD81 expression densities on the vesicles, A151 loaded Apoptotic blebs were the highest
expressing ones among others (Figure 4.25).
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Figure 4.23: surface Characterization of Different RAW derived vesicles were labeled with
CD81-PE Ab and Annexin-V-FITC. There are three samples from each vesicle type; unmod-
ified, reconstituted and A151 loaded. Vesicles were analyzed with flow cytometer.
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Figure 4.24: Effect of lyophilization on CD81 surface protein presentation of EVs. Different
RAW derived vesicles were labeled with CD81-PE. There are three samples from each vesicle
type; *: unmodified, Recons: reconstituted, A151: A151 loaded.
Figure 4.25: Analysis of CD81 presentation among various RAW derived vesicles. Micropar-
ticles and exosomes acquired from normal and apoptotic RAW cells were labeled with CD81-
PE Ab and analyzed by flow cytometry. A: Apoptotic vesicles.
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4.4.2 Nucleic Acid detection from EVs either unloaded or loaded
with A151 ODN
A151 loading to the MPs and A.Blebs greatly increased the nucleic acid content (Figure 4.26).
Acridine Orange (AO) is a cell membrane permeable dye which stains
Figure 4.26: Nucleic acid content of MPs and A.Blebs derived from RAW cell lines. Unmod-
ified, reconstituted with and without A151 vesicles were stained with AO dye. AO stains
single and double stranded nucleic acids differentially. Analysis were made by Accuri C6. *:
unmodified, Recons: reconstituted, A151: A151 loaded.
single and double stranded nucleic acids distinctly; while green signal indicates presence of
either ds DNA or dsRNA orange signal indicates either ss DNA or ssRNA. Because A151 can
accommodate complex G-tetrad structure, AO stains as if it is a double stranded structure.
There is slight increase in ss nucleic acid signal probably because of the tattered A151
strands. Loading of A151 to the exosomes also demonstrated a similar increase in nucleic
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acid content (Figure 4.27).
Figure 4.27: Nucleic acid content of exosomes derived from naive and apoptotic RAW cell
lines. Unmodified or reconstituted with and without A151 vesicles were stained with AO
dye. Recons: reconstituted, A151: A151 loaded.
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4.4.3 Immunosuppressive effects of EVs associated with A151
A151 is a promising immunosuppressive agent. After observing that A151 can be
loaded/associated within EVs, we planned to test the immunosuppressive effect of A151
loaded EVs on immune cells that were simultaneously stimulated with different TLR ligands.
In suppression experiments 5µg of A151 added per one million vesicles for lyophilization and
subsequent reconstitution. Data revealed that when A151 was loaded to EVs its suppressive
capacity greatly augmented against either a TLR9 ligand, K23 CpG ODN (Figure 4.28)
or a TLR7 ligand, R848 (Figure 4.29) mediated immune activation. As mentioned earlier,
different EVs (i.e. Exosomes, MPs, Apoptotic Exosomes, Apoptotic Blebs) were loaded with
A151 ODN via Rehydration-Dehydration Technology (please see Section 3.2.13 for more de-
tails) and incubated with mouse spleen cells (from C57/BL6) that were simultaneously either
treated with 0.3 uM K23 CpG ODN (Figure 4.28), or 1ug/ml R848 ligand (Figure 4.29).
Our in vitro suppression assay results suggested that upon K23 CpG ODN stimulation when
low dose free A151 (3 µg/ml) was added to the culture medium, it could only suppressed
≈50% of IL-6 production from splenocytes. Supporting our hypothesis, MP or apoptotic
exosome-loaded with A151 counterparts led to 85% suppression of IL-6 production (please
see Fig 4.28 top panel, left side). At low dose suppression of IL-12 production did not show
any difference with respect to free or EV associated A151 (please see Fig 4.28 bottom panel,
left side). At high doses of A151, however, all of the EV-associated A151 groups success-
fully blocked both IL-12 secretion, while its free counterpart could only induced 50-60%
suppression (please see top and bottom right hand side panels of Fig 4.28).
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Figure 4.28: IL-6 and IL-12 secretion was suppressed by A151 loaded EVs. K23 stimulated
spleen cells were co-incubated with free A151 or EV-A151 formulations for 24 h, and culture
supernatants were collected ans assayed by ELISA. Two concentrations of A151 was used; 3
and 10 µg/ml. K23 concentration is 0.3 µM/ml. Statistical analysis was performed using a
one-way ANOVA test for multiple comparisons. *P < 0.001
Figure 4.29 summarizes the suppression profile upon R848 stimulation of spleen cells. EV
encapsulated A151 was very effective against immune activation mediated by TLR7 ligand.
While free A151 (at either doses) failed to suppress any IL-6 or IL-12 production, EV loaded
A151 at 3µg/ml dose (left panels) was ≈50% suppressive and at 10µg/ml dose (right panels),
it completely shut off both IL-6 and IL-12 production (please check top and bottom panels
of Fig 4.29).
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Figure 4.29: IL-6 and IL-12 secretion was suppressed by A151 loaded EVs. R848 stimulated
spleen cells were co-incubated with free A151 or EV-A151 formulations for 24 h, and culture
supernatants were collected and assayed by ELISA Two concentrations of A151 was used; 3
and 10 µg/ml. R848 concentration is 1 µg/ml. Statistical analysis was performed using a
one-way ANOVA test for multiple comparisons. *P < 0.001
To differentiate whether the immunosuppressive effect was solely regulated by associated
A151 or empty EVs also contribute to the suppressive action, we designed an additional
control experiment. Similar to above experiments mentioned in Figures 4.28 and 4.29, we
incubated different empty EVs with spleen cells that was stimulated either with K23 (Fig-
ure 4.30) or with R848 (Figure 4.31). In these settings, EVs were devoid of any A151 ODN.
As clearly seen in Figure 4.30, at low doses EVs did not show any appreciable suppression of
IL-6 that was triggered by K23 CpG ODN. But significant suppression of IL-12 was mediated
by these EVs (Bottom panel of Fig 4.30). As for R848 stimulated cells with empty EVs, we
have not seen any EV mediated immune suppression of IL-6, but 50% IL-12 suppression was
mediated by empty EVs irrespective of the dose used for suppression (Figure 4.31).
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Figure 4.30: IL-6 and IL-12 secretion by mouse splenocytes treated with K23 and EVs simul-
taneously for 24 h. supernatants were collected and assayed ELISA. Vesicle concentrations
were adjusted to 6.5 x 105 and 2 x 106/ml, equivalent to the amounts used in Figures 4.28
and 4.29. K3 concentration was 0.3 µM/ml.
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Figure 4.31: IL-6 and IL-12 secretion by mouse splenocytes treated with R848 EVs simulta-
neously for 24 h. 24 hours after the treatments, cell culture supernatant were removed for
cytokine ELISA. Vesicle concentrations were adjusted to 6.5 x 105 and 2 x 106/ml, equivalent
to the amounts used in Figures 4.28 and 4.29. R848 concentration 1 µg/ml.
Collectively, this data implicated that suppression of either TLR9 or TLR7 ligand medi-
ated IL-6 production was regulated mainly by EV associated A151, whereas, both EVs and
A151 collectively contributed suppression of IL-12 production by immune cells.
Throughout these in vitro assays, EV derived immune activation was not assessed. To
check this possibility, spleen cells were treated with empty EVs for 24h. Secretion of IL6
and IL12 was analyzed by ELISA from culture supernatants. As expected there was no
significant immune activation triggered by empty EVs (Figure 4.32).
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Figure 4.32: Immunstimulatory effect of RAW derived EVs on mouse spleen cells. All
vesicles were administered without any ligand. After 24 hours, cell culture supernatant were
removed for IL-6 and IL-12 cytokine ELISA. Two concentrations of A151 and vesicles were
used; 3, 10 µg/ml and 0.65, 2 mil/ml respectively. R848, K23 and A151 were administered
as immunostimalatory and immunosuppressive controls.
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Chapter 5
Conclusion
The major theme of this thesis was to characterize and understand the potential functions
of extracellular vesicles (EVs) isolated from different mouse and human cell lines on immune
cells. Coupled to this, we attempted to identify the immunomodulatory roles of these vesicles
as suitable nanocarriers of TLR ligands that were liberated from infected cells. The in vitro
and in vivo internalization kinetics and differential accumulation degrees of EVs by different
immune cells were described. Based on this knowledge clues regarding to EV mediated
distant transmission and propagation of ongoing infection were investigated. Lastly, in order
to document that these secreted EVs could be harnessed as a suitable drug carriers, an
immunosuppressive DNA motifs, namely, A151 ODN was externally loaded within EVs and
their improved immunosuppressive potential against down-regulating an ongoing immune
activation mediated by bacterial by-products was demonstrated in tissue culture settings.
The findings in this thesis revealed that different forms of EVs (exosomes, microparti-
cles and their apoptotic forms) could be isolated and purified from cell culture supernatants
at high yields. Moreover, their physiochemical characterization studies via DLS or AFM
confirmed their vesicular nature and retention of their proper sizes even after reconstitution
followed by lyophilization (i.e. size ranges were 100-150nm for exosomes, and 250-500nm for
microparticles, respectively). Interaction of these EVs in culture with immune cells isolated
from mouse spleens implicated that relevant target cells internalize and bind these secreted
vesicles at a different rate and kinetics and both parent and target cell types are the determi-
native factors behind internalization and association of the cells. Kinetics of internalization
and degree was dependent on Cell:MP ratio. Higher this ratio much rapid/faster internaliza-
tion occurs. Our data suggested that in culture the MPs were mostly internalized by B-cells
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where as T-cells did absorbed very few MPs. Also, each MPs type indicated different affini-
ties to the target spleen cells. On one hand, NIH-3T3 derived MPs were the most absorbed
one by B-cells and DCs but RAW MPs indicated the greatest affinity for macrophages, T-
cells and DCs. On the other hand EG-7 MPs demonstrated the fewest affinity for all cells
except B-cells. This differential internalization was critical to describe the contribution of
vesicular cargo delivery to specific immune cells and subsequent alteration of the immune
activation upon EV association.
Intaperitoneal(IP) injection of MPs demonstrated a completely different internalization
and uptake profile. Injected MPs were mostly absorbed by peritoneal macrophages whereas
peritoneal B-cells embodied very few MPs. Also, RAW MPs demonstrated significantly
higher affinity for macrophages than other MPs. The distinct profiles of in vivo and in
vitro internalization studies indicated distinct characteristics of same cell type on different
locations, such as peritoneal and splenic B-cells. Although, the internalization studies were
based on a few cell lines derived MPs and principal immune cells, we believe that our
approach provided a wide perspective into the realm of EVs. Further internalization and
uptake characteristics of MPs secreted from different cells may provide essential knowledge
about the function of distinct MPs as well as their potential for therapeutic studies such as
modified EVs and targeted drug delivery.
Stimulation experiments with MPs associated with TLR ligands indicated the affinity of
cell derived MPs to TLR ligands. Also, when immunostimulatory activities of TLR ligand-
associated MPs were compared with free TLR ligands we observed that MP association
provides amplified immune responses. Lots of previous studies in field demonstrated that
infected cells can secrete pathogenic by-products through MPs and subsequently propagate
immune responses on other cell. However, our results demonstrated the potential role of MPs
in amplification of immune responses through transportation and presentation of pathogenic
molecules in extracellular milieu.
Loading of A151 to MPs significantly enchanced its immunosuppressive effect on TLR9,
TLR7/9 triggered immune activations. Especially, when free A151 did not influence R848
based IL-6 and IL-12 secretions, MP-A151 completely inhibited proinflammatory cytokine
secretion. Although, suppressive effect of MP-A151 has not been examined in vivo yet, our
finding still indicates that MPs are potential delivery systems for therapeutic synthetic DNA
motifs.
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Appendix A
Buffers, Solutions, Culture Media
Blocking Buffer (ELISA)
 500 ml 1x PBS
 25 grams BSA (5%)
 250 µl Tween20 (0,025%)
Mixture is stirred until fully homogenized. Stored in −20 ◦C.
T-cell Buffer (ELISA)
 500 ml 1x PBS
 25 ml FBS (5%)
 250 µl Tween20 (0,025%)
Stirred until fully homogenized. Stored in −20 ◦C.
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Wash Buffer [ELISA]
 500 ml 10x PBS
 2.5 ml Tween20
 4.5 lt ddH2O
PBS (Phosphate Buffered Saline) [10x]
 80 grams NaCl
 2 grams KCl
 8,01 grams Na2HPO4 . 2H2O
 2 grams KH2PO4
 1 lt ddH2O
Stirred until fully homogenized. pH is adjusted to 6.8. Filtered and autoclaved before
use.
PBS-BSA-Na azide
 500 ml 1x PBS
 5g BSA (1%)
 125 mg Sodium Azide (0,25%)
Stirred until fully homogenized. Stored at +4 ◦C.
Annexin-V Binding Buffer [10x]
 0.1 M HEPES
 1.4 M NaCl
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 25 mM CaCl
Dissolved in ddH2O, pH adjusted to 7.4 and diluted to 1x with ddH2O before use. Stored
at +4 ◦C.
RPMI-1640 (Lonza)
 2 % : 10 ml FBS (FBS = inactivated at 55 ◦C.)
 5 % : 25 ml FBS
 10 % : 50 ml FBS
 5 ml Penicillin/Streptomycin (50 g/ml final concentration from 10 mg/ml stock)
 5 ml HEPES (Biological Industries), (10 mM final concentration from 1M stock )
 5 ml Na Pyruvate, (0,11 mg/ml final concentration from 100mM, 11 mg/ml stock)
 5 ml Non-Essential Amino Acids Solution, (diluted into 1x from 100x concentrate
stock)
 5 ml L-Glutamine, (2 mM final concentration from 200 mM, 29.2 mg/ml stock)
Added into 500 ml medium. Stored at 4 ◦C.
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Appendix B
Figures
Figure B.1: MP uptake by B cells in PEC. A) CFSE positivity among gated B cells, B) B
cell ratio in CFSE positive cells. For more detail see Figure 4.17
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Figure B.2: MP uptake by T cells in PEC. A) CFSE positivity among gated T cells, B) T
cell ratio in CFSE positive cells. For more detail see Figure 4.17
Table B.1: CD11b, CD11c, CD3, B220 cell population percentages in PEC. For more detail
see Figure 4.17
CD11b CD11c CD3 B220
Naive 59.9±0.9 2.0±0.6 11.1±2.2 22.5 ±0.2
RAW 56.5±5.4 1.5±0.3 16.7± 0.6 26.1 ±6.2
EG-7 57.2±0.8 1.1±0.0 11.0± 3.5 33.5 ±7.1
NIH-3T3 75.6±0.7 1.2±0.2 10.0± 0.4 16.0 ±1.0
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Figure B.3: MP uptake by macrophage cells in PEC. A) Percentage of macrophages which
obtained CFSE-MPs, B) Macrophage ratio among CFSE positive cells. For more detail see
Figure 4.17
Table B.2: CD11b, CD11c, CD3, B220 cell population percentages in spleen cells . For more
detail see Figure 4.17
CD11b CD11c CD3 B220
Naive 4.3± 0.2 3.1± 0.2 25.5± 2.1 63.1± 1.7
RAW 5.1± 0.9 2.4± 0.6 25.7± 1.9 68.4± 2.1
EG-7 4.9± 1.2 3.3± 0.4 23.2± 5.6 63.7± 3.7
NIH-3T3 4.5± 0.4 2.7± 0.1 24.6± 1.6 66± 1.8
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Figure B.4: Uptake of MPs by DCs in mice PEC. A) CFSE positivity in gated DCs, B) DC
ratio among CFSE positive cells. For more detail see Figure 4.17
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